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ABSTRACT 
 
Introduction 
Namibia is currently coping with a dual burden of human immunodeficiency (HIV) and 
HIV-associated tuberculosis (TB). In 2010, HIV prevalence was 18.8%, the TB case 
notification rate was 634 per 100,000 population, while TB/HIV co-infection was 58% in 
2009. There were 372 reported cases of drug-resistant TB (DR-TB) in 2009.  
This study assessed the prevalence, profile and outcome of adverse events (AEs) 
associated with the treatment of DR-TB, and risk factors for the adverse events. 
Methodology 
The researcher used a cross-sectional design. Data was collected from the treatment 
records of all patients treated for DR-TB (N = 59) at the study facility between January 
2008 and February 2010. Descriptive statistics were used to describe the frequency of the 
adverse events and logistic regression to analyse the association between possible risk 
factors and (specific) adverse events, with stratification (sub-group analysis) and 
multivariate analysis to adjust for measured confounders. Results of logistic regression 
analysis are reported as odds ratio (OR), 95% confidence interval (CI) and p-value, 
where p<0.05 was considered to be statistically significant. 
Results 
A total of 141 adverse events were experienced by 90% (53/59) of patients in the sample. 
HIV-associated TB occurred in 31 (53%) of the sample. The prevalence of 
gastrointestinal tract (GIT) adverse events was 64%, tinnitus 45%, joint pain 28% and 
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decreased hearing 25%. Abdominal pain, rash, nausea, decreased hearing and joint pain 
were found to be more common in people living with HIV than in HIV-negative 
patients.  
Moderate-to-severe adverse events were mostly experienced after four weeks of DR-TB 
treatment (OR 6.4; 95% CI 1.6 – 25.6, p= 0.01). Drug-resistant TB patients who were co-
infected with HIV were more prone to experiencing three or more adverse events (OR 
3.9; 95% CI 1.2 – 13.6, p= 0.03). Patients treated with zidovudine-based ART were at an 
increased risk of experiencing nausea (OR 7.5; 95% CI 1.1 -51.5, p=0.04). Females were 
associated with an increased risk of skin rash (OR 15.7; 95% CI 1.7 – 143.7, p=0.01). The 
use of cycloserine-based DR-TB regimens was associated with joint pain (OR 6.5; 95% 
CI 1.6 – 25.8, p=0.01), while the risk of ototoxicity was associated with the use of 
amikacin-containing regimens (OR 12.0; 95% CI 1.3 – 111.3, p=0.03). 
Conclusions 
Adverse events were found to be more common among patients treated for DR-TB (90% 
prevalence), particularly during the intensive phase of TB therapy. Most of these 
adverse events were mild and tolerable. Some adverse events were more common 
among DR-TB patients who were co-infected with HIV than in HIV-negative patients. 
The characteristics and risk factors of the serious adverse events need further research. 
The use of cycloserine-based DR-TB regimens was associated with joint pain. Findings 
of the risk factor analysis are inconclusive because of the small sample size, which 
severely limited the power of the study.  
Clinicians should invest more time in the prevention and management of adverse 
events, and should pay greater attention to the needs of HIV co-infected DR-TB patients 
who are using second-line anti-TB medications, especially those who are concomitantly 
undergoing treatment using antiretroviral medicines.
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1. INTRODUCTION 
Background 
The global and national epidemiology of tuberculosis  
Infection by Mycobacteria tuberculosis continues to be a growing global public health 
problem that afflicts large numbers of human populations across the globe, and 
particularly those in sub-Saharan Africa, including Namibia (WHO, 2008a). According 
to the World Health Organization’s (WHO) Global Tuberculosis Control Report of 2008, 
the global incidence of TB was estimated to be 9.2 million new cases in 2006 (i.e. 139 
new cases per 100,000 population), with Africa registering the highest incidence per 
population of  363 per 100, 000 people (WHO, 2008a: 3). The 2007 data relating to 
Namibia’s TB profile which is available in the WHO TB database, cites Namibia’s 2007 
TB incidence as high, with 767 cases per 100,000 population, which was more than twice 
as high the average incidence for other countries in the African region. Namibia’s TB 
mortality rate was reported to be equally high in 2007 (102 cases per 100,000 
population), while the HIV and TB co-infection was 67 percent (WHO, 2009a). 
 
The 2009 Global TB Control: WHO Report indicates that Namibia ranked second (after 
Swaziland) as the country with the second highest TB case notification rate. This 
information is based on the TB notification data of 2006 (see Figure 1.1 below). In spite 
of this, Namibia is not considered to be among the 22 high TB burden countries because 
of its small population, which was estimated in 2008 to be 2,065,224 (Central Bureau of 
Statistics, 2006). In reality, this results in low absolute numbers of patients with TB 
when one compares Namibia to the other more densely populated countries of the 
world. 
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Figure 1.1: The ten countries with the highest TB case notification rates in the world 
Source: WHO, 2009 
 
The burden of tuberculosis disease in Namibia peaked in the year 2004, when the case 
notification rate stood at 822 cases per 100,000 population. But since 2004, this rate has 
steadily declined because of the number of the well-designed and focused TB 
prevention, treatment and control measures that have been implemented by the 
National Tuberculosis and Leprosy Control Program (MoHSS, 2010) as shown in Figure 
1.2 below.   
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Figure 1.2: Trends in TB case notification rates, 1998-2009, Namibia 
Source: MoHSS, 2010. [Note the slight difference in the MoHSS and WHO figures for 
2006.  
 
The burden of drug resistant tuberculosis disease 
The specter of drug-resistant TB poses a serious threat to public health throughout the 
world, but especially in southern Africa. There were an estimated 0.5 million cases of 
MDR-TB globally in 2007, with South Africa accounting for 16, 000 of these cases 
(WHO, 2009b: 2).   
 
According to the World Health Organization’s guidelines on the treatment of 
tuberculosis (WHO, 2010a), the resistance of the mycobacterium to anti-tuberculosis 
chemotherapy can range from resistance to one drug (mono-resistance) to resistance to 
more than one anti-TB drug, other than both isoniazid and rifampicin (poly-resistance) 
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to multidrug resistance, which is the resistance to both of the two most commonly used 
anti-TB drugs (rifampicin and isoniazid). While multi-drug-resistant tuberculosis 
(MDR-TB) is caused by bacteria that are resistant to at least isoniazid and rifampicin 
(the two mostly effective anti-TB drugs), extensively drug-resistant TB (XDR-TB) is 
caused by bacteria that are resistant to isoniazid and rifampicin as well as to any 
fluoroquinolone and any of the second-line anti-TB injectable drugs, amikacin, 
kanamycin or capreomycin (WHO, 2010a).  
 
The emergence and spread of drug-resistant TB (MDR and XDR TB) is a major public 
health concern. Since the incidence of drug-resistant TB is increasing, more and more 
patients are being exposed to anti-tuberculosis treatment using the less efficacious 
second-line TB regimens, which are also associated with an increased frequency of 
adverse effects (WHO, 2008a) and which result in increased frequency of TB drug-
induced morbidity and mortality. Other unfortunate consequences of MDR and XDR 
TB are that the required length of time for treatment is usually prolonged; it has low 
cure rate of about 60% for MDR-TB (WHO, 2010b), and it is costly both to patients (the 
cost has been estimated by Tupasi and colleagues at US$ 837 per patient) and to the 
health system (the cost has been estimated at US$ 3,355 per patient) (Tupasi et al., 2006).  
 
The emergence and spread of drug-resistant TB is best prevented by ensuring that only 
quality-assured TB medicines are prescribed for patients; that patients maintain the 
required levels of adherence throughout the treatment period, and that the patients 
themselves and everyone who comes into contact with them observe optimal infection 
control practices (WHO, 2009b). This study focuses on the patient’s experience of those 
adverse reactions that are associated with second-line TB medicines. The prevention 
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and control of adverse drug effects necessitates close clinical and laboratory monitoring, 
adjunctive treatment, specific medical management, hospitalization and skilled nursing 
care, where necessary. These requirements increase the cost of TB chemotherapy, and 
the costs associated with them have to be borne by the patients themselves and by the 
healthcare system. Such procedures and specialized care reduce the personal 
availability and labor productivity of affected individuals and may thus pose a threat to 
the economic wellbeing of individuals, their families and of the community as a whole 
(WHO, 2006a; Tupasi et al., 2006).  
 
Risk factors for drug resistant tuberculosis 
A number of risk factors have been implicated in the genesis and development of drug-
resistant TB. The WHO 2010 Global Report on MDR and XDR-TB surveillance mentions 
the following key risk factors that are associated with drug-resistant tuberculosis 
(WHO, 2010b).  
1. Irregular use of anti-TB drugs by an individual 
2. Behavior associated with males (being an adult male) 
3. The existence of HIV infection in a patient prior to TB infection  
4. The peculiar susceptibility of young adults (and particularly people between the 
ages of 15 and 44 years) 
 
Drug resistant tuberculosis in Namibia 
In Namibia itself, resistance to available first-line and second-line anti-TB medicines is 
an extremely serious health hazard that threatens to reverse the gains that have accrued 
to Namibia as a result of the success that the National Tuberculosis and Leprosy 
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Program achieved in reducing the burden of TB throughout the country. Table 1 
provides a summary of the startling increases in the number of cases of drug-resistant 
TB that were reported between 2007 and 2009. 
Table 1.1: Total reported and confirmed numbers of DR TB cases for the period 2007-2009, Namibia 
DRUG RESISTANCE CATEGORY  2007 2008 2009 
Number of cases with confirmed MDR-TB (excluding 
XDR-TB)  
116 201 275 
Number of cases with confirmed poly-drug-resistant 
TB  
7 47 80 
Number of cases with confirmed XDR-TB  3 20 17 
Totals 126 268 372 
Source: MoHSS, 2010.    
 
Drug resistant tuberculosis (DR-TB) is associated with high morbidity and mortality 
rates, especially among HIV-infected patients, who may account for more than 50% of 
TB cases in Namibia. Globally, the rate of MDR-TB in 2007 among new TB cases was 
1.6% in contrast to the figure of 8% among previously treated TB cases (WHO, 2009a). 
In Namibia, it has been observed that drug-resistant tuberculosis affects mostly young 
and economically productive adults (with a mean age of 35 years), and males in 
particular (MoHSS, 2010). Almost all these cases of pulmonary tuberculosis are those 
who have either failed category 1 treatment or who have relapsed after successful 
treatment with category 1 treatment (MoHSS, 2010). In 2009, the majority of reported 
DR-TB cases came from six of the following 13 regions of Namibia: Kavango, Khomas, 
Otjozondjupa, Ohangwena, Oshana and Erongo regions (MoHSS, 2010). 
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In response to the rapidly growing threat of drug-resistant tuberculosis in Namibia, the 
Ministry of Health and Social Services, with support from its development and 
technical partners, is now implementing a program of DR-TB (PMDT) management 
which has been designed to address and remedy some of the difficulties that have 
undermined efforts to prevent the emergence and spread of resistance to anti-TB 
medicines. Some of the interventions in the PMDT program include the ongoing 
training of health care workers in the effective management of DR-TB, and the 
establishment of a Central Clinical Review Council (CCRC) for DR-TB, which is charged 
with the responsibility of reviewing the clinical histories of all DR-TB patients, 
recommending appropriate treatment regimens for the patients, and providing 
guidance and technical oversight for the medical management of all MDR-TB patients. 
 
Diagnosis and surveillance of drug-resistant TB in Namibia 
The Namibia Institute of Pathology (NIP) provides most of the routine biomedical 
laboratory testing services needed by state-operated hospitals and primary care health 
facilities. The NIP has a central reference laboratory in the capital city of Windhoek, 
where all mycobacterial culture and drug susceptibility testing are undertaken. All 
testing for resistance to first-line anti-TB drugs is also carried out by NIP, while testing 
for resistance to second-line anti-TB drugs is performed by the supranational reference 
TB testing laboratory in South Africa. 
 
While the national surveillance of TB drug-resistance has hitherto been weak, it has 
significantly improved in the past four years because of the use of an electronic TB 
register and the surveillance by the central clinical review council (MoHSS, 2010). The 
implementation of a system for the active surveillance of drug-resistance tuberculosis is 
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still being developed and the piloting of the e-TB manager tool is being currently 
undertaken in about six DR-TB treatment facilities in Namibia (Personal 
communication, Dr. Nunurai Ruswa, NTCP: October 2011). 
 
Challenges in chemotherapy of drug-resistant TB  
The treatment of MDR-TB is a complex undertaking that requires long periods of 
continuous treatment, the combination and administration of 5 - 9 different types of 
medicines, and strict and conscientious adherence to the requirements of TB 
chemotherapy. One of the great difficulties is that patients often find it enormously 
difficult to adhere to these long-term second-line treatment regimens, a problem that is 
further compounded when they begin to experience intolerable adverse drug reactions 
(ADRs) (Xu et al., 2009). Patient tolerance of the usually mild side-effects of anti-TB 
drugs is a requirement for achieving complete adherence and successful TB treatment 
outcomes. Unfortunately, however, severe and serious side-effects, by their very nature, 
rapidly become intolerable and unacceptable when they jeopardize the lives and quality 
of life that is experienced by the patient concerned. Adverse drug reactions are 
therefore implicated in the poor treatment adherence shown by many patients (Zaleski, 
2006; MoHSS, 2006; WHO, 2006a; 2007). Fifteen percent (15%) of all patients on MDR-TB 
chemotherapy described severe adverse reactions as the main reason why they failed to 
adhere to treatment regimens (Xu et al., 2009). In another study, up to 23% of TB 
patients were compelled to terminate TB chemotherapy during the intensive phase of 
treatment because of the tremendously adverse effects of the medications (Schaberg et 
al., 1996). As the number of patients being treated for MDR-TB in Namibia increases, the 
exposure of the TB-infected patient population to the risk of serious ADRs also 
increases, and this creates an important public health concern because of the increased 
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risk of TB drug-induced patient harm and its related consequences for the TB control 
program in Namibia.  
 
TB and HIV co-infection in Namibia 
Tuberculosis is one of the most common opportunistic infections observed in patients 
already infected with HIV, and one of the earliest to appear. HIV associated 
tuberculosis in Namibia has fluctuated around 58% over the past five years; it was 59% 
in 2008 and 58% in 2009 (MoHSS, 2010). Drug-resistant tuberculosis is associated with 
high morbidity and mortality rates among HIV-infected patients, although no data is as 
yet available to indicate the prevalence of HIV among patients with DR-TB. 
 
Since HIV disease is a serious public health concern in Namibia, it has aggravated the 
recent TB trends shown in Figure 1.3. Figure 1.3 shows how the rate of TB case 
notification initially increased and then later began to decline in tandem with the 
antenatal HIV prevalence trends for the period between 1998 and 2008. (The antenatal 
prevalence of HIV was measured among women who attended antenatal clinics.) 
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Figure 1.3: Relationship between HIV prevalence and TB case notification rates for the period 1998–
2008 
Source: MoHSS (2009, 2010) 
 
When studying TB and HIV co-infection in a country with high burdens of both 
diseases such as Namibia, it is important to understand and be aware of how the 
various possible combinations of patient sub-groups of co-infection in terms of drug 
sensitivity and patterns of resistance to Mycobacterium tuberculosis and to the human 
immune deficiency virus in the population, present and show themselves. The matrix in 
Figure 1.4 (below) shows the four sub-groups that arise, and the relative availability of 
data about each of the sub-groups of TB/HIV co-infection in Namibia. The figure shows 
that the majority of affected patients are those with drug-sensitive TB and/or drug-
sensitive HIV. These categories are followed by those with drug-resistant TB and drug-
sensitive HIV co-infection. This study focuses on patients with drug-resistant TB and 
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drug-Sensitive HIV co-infection because of the number of DR-TB patients who are co-
infected with drug-resistant HIV, is relatively low.  
 
  Type of tuberculosis infection 
  
Drug-sensitive 
TB 
Drug-resistant 
TB 
H
IV
 i
n
fe
ct
io
n
 
Drug sensitive 
HIV 
The majority of 
patients are in 
this sub-group. 
Relatively more 
data is available. 
 
Some data is 
available 
Drug resistant 
HIV 
Limited amount 
of data is 
available. 
 
Limited amount 
of data is 
available 
 
Figure 1.4: Four possible sub-groups of patients with TB/ HIV co-infection 
 
Research problem  
At the time of conceptualizing and writing the proposal for this study, very little useful 
documented information about the occurrence, rates and profile of adverse reactions to 
second-line anti-TB medicines and their predisposing factors in the Namibia’s National 
Tuberculosis Control Programme (NTCP), was available. This lack of information has 
made it difficult for clinicians to properly manage adverse reactions and optimize TB 
treatment success in individual patients. It has also made it difficult for TB program 
managers to effectively plan, design and implement strategies or interventions for 
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improving the quality of TB treatment and care in TB programs. Doctor D. Panganai 
expressed a keen interest to document the occurrence of adverse reactions of second-
line anti-TB medicines in Namibia (Personal communication, Dr. D. Panganai, TB 
program manager: February 2009). 
 
This lack of vitally important information indicated the need for local studies that 
would gather accurate information about the occurrence, rates, characteristics, 
predictability and possible risk factors of adverse reactions to second-line anti-TB 
medicines in Namibia.  
 
Study significance 
A key challenge faced by clinicians when treating patients with drug-resistant TB in 
Namibia is their limited ability to predict (for an individual patient) the probability of 
major adverse effects as a result of a particular second-line anti-TB regimen (or a 
component drug in the regimen) because of lack of precise local data about patient risk 
factors for anti-DR-TB medicine-related adverse events. An accurate knowledge of the 
risk factors associated with particular adverse reactions to medicines will help clinicians 
and doctors to design interventions to prevent or minimize the future occurrence of 
adverse effects medicines in patients (Pirmohamed, Breckenridge, Kitteringham and 
Park, 1998; Riedl and Casillas, 2003). But such knowledge involves a thorough and 
detailed understanding and evaluation of individual patient adverse drug effect risk 
factors, as well as an analysis of base-line patient characteristics, contextual and genetic 
factors. This study was therefore designed to supply the information that was needed 
about the types, frequency, characteristics and risk-factors associated with adverse 
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events of drug-resistant anti-TB chemotherapy so that clinicians could make informed 
choices about the attention, resources and efforts that would be needed for the 
prevention and clinical management of the serious adverse reactions that are frequently 
caused by second-line anti-TB medicines, as recommended by Zaleskis (2006). 
 
The setting: A public TB treatment facility in Walvis bay District, 
Namibia 
The research was conducted in a TB treatment facility in the Walvis Bay District of 
Namibia. Walvis Bay District is located on the Atlantic coast of Namibia. The settlement 
and its surroundings contain Namibia’s main sea port and harbor. Its main economic 
activity includes port operations and international sea transport, fish processing and 
tourism. At the time of this study, the Walvis Bay TB treatment facility was serving the 
second largest number of patients for second-line treatment in Namibia after Katutura 
Intermediate Hospital (MoHSS, 2006). On average, there are usually 20-25 patients for 
second-line TB treatment at any one time in the TB ward in this facility. These patients 
are admitted to the TB ward and are initiated into second-line treatment that takes the 
form of six months of intensive chemotherapy. Continuation therapy is maintained 
through a facility-based DOTS-plus program that is run by the health center nearest to 
the patient. Patients visit the health facility every day between Monday and Friday 
inclusive for their daily dose of anti-TB medicines.  
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2. LITERATURE REVIEW 
Definitions of key concepts and terms 
These definitions and descriptions have been adapted from the following sources: UMC 
(Uppsala Monitoring Center) (2000); Riedl and Casillas (2003), and WHO (World Health 
Organization) (2007). 
 
Adverse [drug] reaction (ADR): An adverse [drug] reaction (ADR) is an adverse 
response to a medicine, which is noxious and unintended and which occurs at doses 
normally recommended for use in humans. 
 
Side effect: A side effect is any unintended effect of a pharmaceutical product occurring 
at doses normally used in humans, which is related to the pharmacological properties of 
the drug. 
 
Adverse event or experience: An adverse event or experience is any untoward medical 
occurrence that may present during treatment with a medicine but which does not 
necessarily have a causal relationship to the treatment. 
 
Unexpected adverse reaction: An unexpected adverse reaction is an adverse reaction, 
the nature or severity of which is not consistent with domestic labeling or marketing 
authorization, and which is not expected from the characteristics of the drug. 
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Serious adverse events are those that: 
 are life-threatening 
 cause or prolong hospital admission 
 cause persistent incapacity or disability  
 are sometimes caused by misuse or dependence to a particular drug 
 
Avoidable (preventable) adverse reactions: Avoidable adverse reactions are those that 
can be predicted and that can therefore be prevented from happening. 
 
Seriousness of ADRs: The seriousness of adverse drug reactions is based on the 
seriousness of the outcome or harm caused to the patient.  
 
Severity of ADR: The severity of an adverse reaction denotes the intensity of the effect, 
which may be mild, moderate or severe. 
 
Short-term ADR: A short-term ADR occurs within a reasonably short interval after 
administration (such as minutes or days after the administration of a medicine). 
 
Long-term ADR: A long-term ADR occurs after the passage of a reasonably long period 
of time (months or years) after the administration of a medicine. 
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Type A and B adverse effects 
Type A adverse effects: Type A adverse effects are those that are caused by the 
heightened (exaggerated) pharmacological effects of a drug. They are fairly common, 
predictable, dose-related, and are avoided by using doses that are better tolerated by an 
individual patient. 
 
Type B adverse effects: Type B adverse effects are generally rare, unpredictable and may 
be serious. They may be immunological or non-immunological and occur in patients 
with often unknown predisposing conditions. 
 
Rare adverse event: A rare adverse event is an event with a probability frequency of 
between 1 in 10,000 and 1 in 1,000. 
 
Spontaneous reporting system: A spontaneous reporting system is a system whereby 
case reports of suspected adverse drug events are voluntarily submitted by health 
professionals, patients and pharmaceutical manufacturers to the national drug 
regulatory authority. 
 
Classification and coding of ADRs 
Adverse reactions may be described and coded in terms of the body’s systems and 
organs by using the WHO Adverse Reaction Terminology (WHO-ART) or the Medical 
Dictionary for Drug Regulatory Activities (MedDRA). 
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Drug-Resistant TB definitions (MoHSS, 2006) 
• Mono-resistance: TB that is resistant to a single drug  
• Poly-resistance: TB that is resistant to more than one drug, but not to the 
combination of isoniazid and rifampicin  
• Multidrug-resistance (MDR): TB that is resistant to at least isoniazid and 
rifampicin  
• Extensively drug-resistance (XDR): TB that is MDR as well as being resistant to 
fluoroquinolones and at least one of the three injectable drugs (amikacin, 
kanamycin, capreomycin)  
 
 
Principles of the Treatment of Drug-Resistant Tuberculosis 
The fourth edition of the World Health Organization guidelines on the treatment of 
tuberculosis recommends the following principles for the treatment of drug-resistant 
tuberculosis by national tuberculosis control programs (WHO, 2010a). 
 According to the guidelines, the aims of the treatment of tuberculosis are to: 
 Cure the patient and restore quality of life and productivity 
 Prevent death from active TB or its late effects 
 Prevent the recurrence of TB and the relapse of the patient 
 Reduce the degree of transmission of TB from the patient to others 
 Prevent the development and transmission of drug resistance. 
These guidelines encourage the regular monitoring of patients in order to facilitate the 
completion of treatment and to allow the identification and management of any adverse 
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effects from the anti-TB medicines. In this process, the cohort analysis of TB treatment 
outcomes is emphasized, especially in patients with drug-resistant tuberculosis. 
 
There are five groups of anti-TB drugs that are recommended for the treatment of MDR-
TB. Anti-tuberculosis drugs in Group 1 are the first-line oral agents; Group 2 are 
injectable agents; Group 3 are fluoroquinolones; Group 4 are oral bacteriostatic second-
line agents, and Group 5 are agents with an as-yet unclear role in the treatment of TB. In 
composing a regimen for treating drug-resistant tuberculosis, the following basic 
principles must be adhered to: 
• Use any first-line drug that is likely to be effective (Group1). 
• Include aminoglycoside or capreomycin (Group 2). 
• A fluoroquinolone should always be used if deemed likely to be effective (Group 
3). 
• Use the remaining Group 4 drugs to make a regimen of at least four effective 
agents. 
• Use Group 5 drugs as needed to make a regimen of at least four effective agents. 
• The initial phase of second-line therapy occurs in a referral hospital. 
• All doses of second-line therapy must be directly observed for the entire 
duration of therapy. 
– Use a community-based DOT approach where possible. 
• Second-line therapy is given for all seven days per week, but the injectable drug 
need only be given for six days per week, with one day of rest (for example. on 
Sunday). 
 
The Namibia Ministry of Health and Social Services (National Tuberculosis and 
Leprosy Control Programme) has adopted an individualized DR-TB treatment 
 
 
 
 
- 19 - 
 
approach. In terms of this approach, patient regimens are custom-made, and are based 
on the drug susceptibility testing (DST) of first-line and additional second-line drugs 
(MoHSS, 2006). The recommended second-line anti-TB medicines for the intensive and 
continuation phases of MDR-TB treatment are shown in Table 2.1. The combination of 
several drugs prevents the further development of resistance because it avoids the 
selection of naturally resistant mutants.Because of widespread concerns about the loss 
of efficacy due to patient resistance to ciprofloxacin and the emergence of a higher rate 
of serious adverse effects caused by amikacin, these two drugs were removed by 
Namibia’s Ministry of Health and Social Services from the list of recommended drugs in 
2008. 
Table 2.1: Recommended second-line anti-TB medicines in Namibia 
Initial Phase Continuation Phase 
Medicines Duration in 
months of 
administration 
Medicines Duration in 
months of 
administration 
Kanamycin  
Ethionamide  
Cycloserine  
Levofloxacin  
Pyrazinamide  
+/-Ethambutol  
Pyridoxine 
At least 6 months 
and 4 months  
post-culture 
conversion  
Ethionamide  
Levofloxacin  
Cycloserine  
At least 18 months 
(Source: MoHSS, 2006:74) 
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Prevalence of adverse effects of second-line anti-TB medicines  
Various studies have reported a high frequency of the occurrence (43-95%) of at least 
one adverse reaction, of any type and characteristic, to anti-TB medicines (Nahar et al., 
2006 [N=64]; Yee et al., 2003 [N=430]; Furin et al., 2001 [N=60]; Chhetri et al., 2008 
[N=137]; Kishore et al, 2008 [N=326]; and Gholami et al., 2006 [N=83]). In general, 
second-line anti-TB regimens have been described as having a higher prevalence of 
adverse effects (up to 95%), when compared to first-line regimens, where the prevalence 
of adverse effects was 50% in the study by Nahar et al., (2006). 
One study in a TB treatment facility in Iran described the most frequently reported 
adverse reactions among patients on anti-TB medicines to have been those that involve 
the hepatobiliary system (37%) and the gastro-intestinal system (21%), (Gholami et al., 
2006).  In addition to this, most (i.e. about 50%) of adverse reactions to anti-TB 
medicines have been graded as mild, (Kishore et al., 2008), while serious adverse 
reactions were reported to appear in between 2.5% and 11% of patients (Gholamiet et al., 
2006; Koshore et al., 2008).  
 
Assessing causality of adverse effects to second-line anti-tuberculosis 
medicines  
The assessment of the causality of adverse effects to second-line anti-tuberculosis 
medicines is complicated by the number of medicines that are involved in the intensive 
phase and the continuation phase regimens. In addition to this, some of the adverse 
effects may be common to a number of medicines, and this makes it difficult to attribute 
particular adverse effects to a specific drug. In addition, the use of fixed dose 
combinations may make it difficult to perform a pharmacological challenge-re-
challenge test for a suspected drug. 
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While the clinical assessment of the causality of a specific adverse drug reaction in 
individual patients may be assessed by making use of the Naranjo algorithm, the WHO 
criteria or any other method, an epidemiologic study is required to investigate risk-
factors at in the population at large (Strom, 2005). The Naranjo algorithm consists of 9 
questions and related scores (Table 2.2). After a researcher has obtained answers to all 
of the nine questions and allocated the score appropriate to the question, it is possible to 
calculate the total score and the probability of an adverse reaction occurring by making 
use of the following scale:  
Definite      > 9  Probable     5–8 Possible      1–4 Doubtful        0    
Table 2.2: The Naranjo algorithm 
Question Yes No Do Not Know 
1. Are there previous conclusive reports about this reaction? +1 0 0 
2. Did the adverse event appear after the suspected drug 
was administered? 
+2 -1 0 
3. Did the adverse reaction improve when the drug was 
discontinued or when a specific antagonist was 
administered? 
+1 0 0 
4. Did the adverse reaction reappear when the drug was re-
administered? 
+2 -1 0 
5. Are there any possible alternate causes (other than the 
drug) that could have caused the reaction? 
-1 +2 0 
6. Was the drug detected in the blood (or other fluids) in a 
concentration known to be toxic? 
+1 0 0 
7. Was the reaction more severe when the dose was 
increased or less severe when the dose was decreased? 
+1 0 0 
8. Did the patient have a similar reaction to the same or 
similar drugs in any previous exposure? 
+1 0 0 
9. Was the adverse event confirmed by objective evidence? +1 0 0 
Source: Naranjo, Busto, Sellers et al. (1981) 
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The risk and burden of adverse events associated with second-line anti-TB 
medicines 
It is important to monitor any adverse events that might be associated with the 
treatment of drug-resistant tuberculosis because of the potential impact they may have 
on the treatment and its outcomes. According to the American Society of Health System 
Pharmacists Technical Bulletins (1995), severe or serious adverse effects of medicines 
may: 
 Require the discontinuation of the use of the offending drug 
 Require the choice of another drug that will have the same therapeutic value 
 Require modification of the dose 
 Require a patient to be admitted to a hospital 
 Prolong the stay of a patient in a health care facility 
 Necessitate supportive treatment 
 Significantly complicated the diagnosis 
 Negatively affect patient prognosis  
 Result in temporary or permanent harm, disability, or death 
Such severe or serious adverse effects may be experienced by patients treated for drug-
resistant tuberculosis using second-line anti-TB medicines. 
 
Medicines that are used in the treatment of drug-resistant Mycobacterium tuberculosis, 
when compared with those that are used for first-line regimens, are far more likely to 
elicit adverse reactions in the patients who are receiving them (Perri and Bonora, 2004; 
Zaleskis, 2006). The use of these medicines requires prolonged treatment, close 
monitoring, and the prevention or minimization of the possible adverse side effects 
(MoHSS, 2006; WHO, 2008b). It should be borne in mind that the adverse reactions 
 
 
 
 
- 23 - 
 
suffered by patients because of the anti-TB medicines that are used in the TB public 
health treatment program, can be a significant cause of morbidity and mortality. These 
factors pose a significant threat to the credibility and success of the program itself 
(WHO, 2006). The frequencies of various adverse events associated with anti-TB 
medicines have been widely identified and described in the relevant literature, and they 
include: abdominal pain (7-30%), nausea and vomiting (5-10%), gastritis (1.7-100%), 
joint pain (6-35%), visual disturbances (0.7-40%), skin reactions (0-43%), hearing loss 
(6%), renal toxicity (3.3-4.7%), hepatotoxicity (1.7-57%), peripheral neuropathy (4.7-16%) 
and psychotic disorders (10%), (Nahar et al., 2006; Yee et al., 2003; Furin et al., 2001; 
Chhetri et al., 2008; Kishore et al., 2008; Gholami et al., 2009). 
 
As has already been noted above, the adverse effects that a patient suffers because of 
anti-TB medicines can hamper that patient’s adherence to the necessary TB treatment 
schedules, and so increase the resistance of Mycobacteria tuberculosis and promote a 
relapse of TB disease (Zaleski, 2006; WHO, 2006; 2007). In their study, Fernandez-Villar 
et al. (2004) reported that moderate to severe hepatotoxicity was caused by anti-TB 
medicines, and that this accounted for 5.5% of the modification or suspension of the 
initial TB treatment regimens, while about 2% of patients had their regimens suspended 
because of other serious adverse drug reactions. It is possible for each medicine that is 
used in the treatment of MDR-TB to elicit serious adverse drug reactions with varying 
degrees of severity and frequency, and this can make it necessary to withdraw the drug 
permanently from the regimen. Figure 4, which was constructed from data obtained by 
from Cox and colleagues, illustrates this same point (Cox, Kalon, Allamuratova, Sizaire, 
Tigay, Sabine et al., 2007).   
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Figure 2.1: Percentage of cases in which second-line anti-TB medicines were discontinued because of 
serious adverse drug reactions on the part of patients 
Source: Cox et al., 2007 
 
Risk factors for adverse events associated with second-line anti-
tuberculosis medicines 
Various patient-related factors have been reported to be associated with an increased 
risk of experiencing an adverse reaction to TB chemotherapy. Yee et al., (2003), using a 
prospective cohort design, coupled with detailed review of cases in whom ADRs 
occurred, studied the major adverse effects of first-line anti-TB treatment in a TB 
treatment program in Canada. They reported a low incidence (1.48 ADRs per patient-
month of follow-up) of major ADRs to the conventional first line anti-TB medicines. By 
using multivariate regression analysis (cox proportional hazards), these investigators 
found that the occurrence of any major adverse effects was associated with being female 
(adjusted hazard ratio 2.5; 95% CI 1.3- 4.7); to being over 60 years of age (adjusted 
hazard ratio 2.9; 95% CI 1.3- 6.3); to being of Asian descent (adjusted hazard ratio 2.5; 
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95% CI 1.3- 5.0), and to having an HIV-positive status (adjusted hazard ratio 3.8; 95% CI 
1.05- 13.4).   
 
The literature review by Riedl and Casillas, (2003) and the case-control study by Pande, 
Singh, Khilnani and Tandon, (1996), both highlighted the role of other potential risk 
factors. These include the habitual consumption of alcohol, co-morbidities, concurrent 
medications, the duration of TB treatment, and the patient’s weight. In a prospective 
study of 50 patients conducted in Nepal by Shakya, Rao and Shrestha (2004), female 
gender, disease extent and poor nutritional status were reported as the most important 
predisposing factors for the hepatotoxicity caused by anti-TB medicines. In addition, 
Pande, et al. (1996) included slow acetylator status as a potential risk factor for isoniazid 
toxicity. Similar risks factors were identified in studies by Nahar et al., (2006); Furin et 
al., (2001); Chhetri et al., (2008); Kishore et al., (2008); Gholami et al., (2009); Mehta et al., 
(2007) and Pirmohamed et al., (1998). Riedl and Casillas (2003), however, whose 
systematic literature review concentrated on adverse reactions of an immunologic 
nature (Type B ADRs), included previous hypersensitivity to related drugs as an 
additional factor. It is instructive to note that these studies focused on either first-line or 
second-line anti-TB medicines (or both regimes) in different demographic, geographic, 
social, cultural and practice settings. This variability in study parameters should be 
considered in the interpretation and comparison of these studies. 
 
In addition to the observational cohort and case-control study designs that have been 
commonly employed in studying adverse reactions of anti-TB medicines in clinical 
practice settings; other methods have also been applied in studying risk factors for the 
ADRs. This includes the nested case-control design applied by Chang, Leung, Yew and 
Tam (2007) and Okwera et al. (1997).  
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The literature review has highlighted limited published research on risk factors 
associated with adverse reactions to second-line anti-tuberculosis treatment in sub-
Sahara Africa, particularly in Namibia. Basing on the above literature review, the main 
factors that could predict the risk of experiencing an adverse reaction to second-line TB 
chemotherapy include: advanced age, female gender, racial/ethnic background, extent 
of the disease, nutritional status, co-morbidities, concurrent medications, the duration 
of anti-TB treatment, pharmacogenetic factors, and patient’s weight.  
 
Concurrent treatment of DR-TB and HIV co-infection 
HIV-associated TB infection is common in Namibia (MoHSS, 2010). The concurrent 
treatment of TB and HIV is known to be beneficial because it is associated with low 
rates of patient morbidity and mortality (Hafkin, Gammino and Amon, 2010). 
 
Co-trimoxazole prophylaxis is indicated for HIV-infected patients who are not yet on 
antiretroviral treatment (ART). Isoniazid prophylaxis, on the other hand, is indicated 
for HIV-infected patients without active tuberculosis disease (MoHSS, 2006; WHO, 
2010a).  
 
The co-treatment of TB and HIV by making use of anti-TB and antiretroviral medicines 
is often challenging for both patients and clinicians. This is caused by an increased 
patient pill burden, overlapping adverse reactions, drug-drug interactions, and the 
immune reconstitution syndrome (IRIS). The concurrent treatment of HIV and DR-TB 
may involve a combined pill burden of 9-10 drugs in the intensive phase of treatment 
and 6-7 drugs during the continuation phase (Venkatesh, Swaminathan, Andrews and 
Mayer, 2011). Such a high pill burden may negatively impact patient adherence to the 
treatment regimen. But the use of fixed-dose combinations of anti-TB and antiretroviral 
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medicines can substantially reduce the patients’ pill burden and hence promote 
adherence to treatment. 
 
Overlapping adverse effects and drug-drug interactions are common occurrences in the 
concomitant treatment of drug-resistant TB and HIV infection. Thus, for example, while 
gastrointestinal intolerance is frequently encountered with the use of zidovudine, 
protease inhibitors, para-aminosalicylic acid and ethionamide, neuropsychiatric adverse 
events are common with the use of efavirenz and cycloserine (Hafkin, Gammino and 
Amon, 2010; WHO, 2010a).  
 
Since didanosine formulations contain an antacid that binds to fluoroquinolones, this 
prevents their absorption and hence reduces their intended efficacy and effectiveness. 
In a similar way, clarithromycin decreases the absorption of zidovudine while 
nevirapine and efavirenz decrease the plasma levels of clarithromycin (Hafkin, 
Gammino and Amon, 2010). 
 
Immune reconstitution syndrome (IRIS) refers to a transient worsening of symptoms and 
signs of tuberculosis disease or radiographic deterioration soon after the initiation of 
antiretroviral therapy, despite reductions in the plasma viral load and evidence of 
immunological recovery (Venkatesh, Swaminathan, Andrews and Mayer, 2011). Such a 
paradoxical response to treatment may be a source of confusion to a clinician who is 
treating a patient with DR-TB who is simultaneously co-infected with HIV and may be 
erroneously misinterpreted by the clinician to be an adverse reaction to anti-TB 
medication. 
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In addition to the clinical challenge posed by IRIS, the diagnosis of tuberculosis 
infection by making use of smear microscopy is usually difficult in people living with 
HIV (MoHSS, 2006). The diagnosis of HIV-associated tuberculosis (and therefore, DR-
TB) , therefore, requires the use of other, more sensitive diagnostic methods. 
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Conceptual framework for studying adverse effects of second-line anti-TB 
medicines  
 
The key factors to consider while quantifying the magnitude of risk of individual 
adverse events and when investigating the risk factors for those events are summarized 
in the conceptual framework in Figure 2.2 below: 
 
 
 
 
 
Disease related factors: 
-What is the effect of other co-morbidities such 
as HIV on the risk of adverse events?  
-Type of TB being treated 
-Extent (severity) of TB disease 
Patient related factors: 
-gender 
-age 
-BMI/Weight 
-nutritional factors 
-Ethnic group 
-Genetic polymorphism such as, for 
example, a slow acetylator status 
 
Outcome- related factors: Adverse events 
-type of adverse event: body system/organ 
-frequency of occurrence 
 
Grading by severity: 
-Mild, moderate, severe  
 
Seriousness of adverse event: 
-hospitalization, disability, death 
 
Proxy markers of occurrence of AEs: 
Emergence of new signs and symptoms; 
Modification/cessation of regimens; Use of 
medicines for treating adverse effects, e.g. 
pyridoxine, corticosteroids; Specific 
biomedical tests ordered 
Therapy related factors: 
Anti-TB medicines exposure 
-previous medicines 
-type of regimen - whether 1st or 
2
nd
 line  
-type of medicines in the 
regimen  
-dosage (dose and frequency) 
-duration/length of exposure 
-number of medicines in the 
regimen 
 
Other medicines for co-
morbidities 
-Antiretrovirals 
 
How great is 
this risk? 
What is the incidence/prevalence? 
What are the 
risk factors? 
Figure 2.2: Conceptual framework for studying the adverse effects of anti-TB medicines 
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Prevention and management of adverse effects of second-line anti-tuberculosis 
medicines  
Although second-line anti-tuberculosis drugs have many more adverse effects than 
first-line anti-TB drugs, the successful prevention and management of these adverse 
effects is possible, even in resource-limited settings such as those in Namibia (WHO, 
2010a). There are several strategies that could be used in the prevention and clinical 
management of adverse effects of second-line anti-tuberculosis medicines. According to 
the WHO guidelines for the treatment of tuberculosis (WHO, 2010a), patients should be 
screened for the side-effects of medication at every DOTS/ DOTS-plus encounter with 
the treating clinician. It is also important that patients should be educated about the 
possible adverse-effects of their anti-TB medications. They should have access to clinical 
and laboratory services to help detect adverse-effects, and they should have access to 
medications to treat adverse effects when they occur. 
 
It is important clinically to particularly monitor patients during the intensive phase of 
treatment of DR-TB so that adverse effects can be promptly detected and properly 
managed. Routine laboratory monitoring is not necessary, according to the World 
Health Organization (WHO, 2010a). Namibia’s National Tuberculosis and Leprosy 
Control Program and the Therapeutics Information and Pharmacovigilance Center 
(TIPC) encourage health personnel to monitor adverse effects of DR-TB medicines by 
teaching health personnel and patients how to recognize and manage the symptoms of 
common adverse effects, and by urging them to report and document such symptoms 
when they occur. Patients are also asked about any such symptoms when they come to 
collect their anti-TB drugs. Adverse events are recorded on the MDR-TB drug side effect 
monitoring form (Appendix 6). 
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Symptom-based approach to managing adverse-effects of anti-TB drugs 
The World Health Organization and National TB Treatment Guidelines recommend 
that adverse effects should be classified as either minor or major (WHO, 2010a and 
MoHSS, 2006). In general, according to these two guidelines, a patient who develops 
minor adverse effects should continue to receive treatment for TB treatment and should 
be given symptomatic (adjunctive or palliative) treatment for the minor adverse side 
effects. If a patient develops a major adverse effect, the treatment or responsible 
(suspected) drug should be discontinued, and the patient should be urgently referred to 
a clinician or health care facility for further assessment and treatment. All patients who 
experience major adverse reactions to medications should be managed in a hospital. 
Zaleskis (2006) recommends the following actions if symptoms of adverse effects occur: 
 Check and verify the dose of the suspected drug. 
 Exclude all other possible causes of the symptom. 
 Determine the seriousness and extent of the adverse effect. 
 Record and document the adverse effect.   
 Gradually re-introduce the suspected drug when the symptoms have 
disappeared. 
 Avoid the possibility of creating resistance to the drug concerned. 
 
Clinicians and other health personnel should be encouraged to apply the above 
principles so that they will be in a position to minimize the occurrence of unpleasant 
side effects and mitigate adverse reactions of DR-TB medicines.  In doing so, patient 
adherence to second-line anti-tuberculosis treatment, and the success of the 
chemotherapy of drug-resistant tuberculosis, may be greatly improved. 
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3. AIM AND OBJECTIVES 
Aim 
The aim of the study was to measure the occurrence of adverse events in adults with 
drug-resistant tuberculosis being managed with second-line TB therapy and investigate 
the association between risk factors and adverse events in a district in Namibia.  
 
Objectives 
The objectives of this study were to: 
1.  Determine the types and frequency of adverse events that occur during the 
treatment of drug-resistant tuberculosis in a sample of patients at the selected TB 
treatment district facility in Namibia  
2. Describe the characteristics, duration and outcomes of the adverse events with 
special reference to HIV-positive and HIV-negative patients  
3. Identify risk factors that are associated with the occurrence of adverse events to 
second-line anti-TB medicines, and examine the influence of HIV infection and 
antiretroviral therapy  
4. Make policy recommendations for the National Tuberculosis Control 
Programme (NTCP)   
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4. METHODOLOGY 
Study design 
The researcher used an observational, cross-sectional, descriptive and analytic study 
design to determine the prevalence of the adverse events of second-line anti-TB 
medicines and to analyze their associated risk factors. The chosen design required the 
researcher to review the patients’ TB treatment records. The descriptive aspect relied on 
an analysis of the quantification of the prevalence (relative frequency) and distribution 
of adverse events to drug-resistant tuberculosis treatment that occurred in the study 
sample. The analytic component compared patient sub-groups and variables in order to 
identify risk factors and to characterize the nature of the association between risk 
factors and the occurrence of the adverse effects caused by anti-tuberculosis medicines. 
Since this was a cross-sectional study, treatment exposure, baseline factors and 
outcomes of interest were all measured at the same point in time. The study therefore 
generated information about the prevalence of the adverse events that occurred during 
the treatment of drug-resistant tuberculosis (Beaglehole, Bonita and Kjellstrom, 1993; 
Enarson, Kennedy, Miller and Bakke, 2001).  
 
Selection of study facility: The researcher purposively selected this TB treatment 
facility for the study because of its relatively good DR-TB treatment adverse event data 
documentation practices at the facility during the time period covered by the study 
(Personal communication, Dr. Nunurai Ruswa, NTCP: July, 2009).  
Adverse events at the facility are monitored daily by the clinical staff treating the 
patient, and these are recorded on a standard MDR-TB drug side effect monitoring form 
that has been standardized by the Ministry of Health and Social Services. There is a 
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separate form for monitoring and recording whatever adverse events might occur in the 
intensive and continuation phase of DR-TB treatment (Appendix 6). 
 
Study population: The study population included all the patients who were treated 
with second-line anti-TB medicines at a specific TB treatment facility in Namibia 
between 01 January 2008 and 24 February 2010, both dates being inclusive.  
 
There were only 59 adults with drug-resistant tuberculosis in the selected facility during 
the study period. All the 59 records were used in the study sample and were examined 
in order to determine the occurrence of adverse events during second-line TB treatment 
and the associated risk factors associated. However, the following sample size 
calculations have been provided to illustrate what the sample size would have been had 
there been sufficient numbers of patients. 
 
Sample selection 
The selected sample included all patients who satisfied the study’s inclusion and 
exclusion criteria. All patients who had been treated with second-line anti-TB medicines 
at the study facility between 01 January 2008 and 24 February 2010 were included. 
Patients with missing records or those with missing data on exposure or outcome 
variables were excluded. 
 
Given that there were only 59 records for the number of TB patients treated with 
second-line TB medicines at the selected TB ward from 01 January 2008 to the day of 
data collection, the researcher decided to include all the patients whose treatment 
records were available on the day of data collection, and whose records corresponded 
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to the defined study period. No sampling was conducted because the available patient 
numbers were fewer than that required for the calculated sample size.  
 
Data collection  
Data were collected retrospectively. Similar retrospective (records review) data 
collection methods have been successfully employed by Furin et al., (2001) and Torun et 
al., (2005) in their study of the adverse effects of second-line anti-TB medicines, and 
these have included risk-factor analyses. 
 
The researcher made use of a structured data collection form to extract the required 
data during the review of each patient’s TB treatment records. Such a form was 
necessary because the record’s review process was retrospective and focused on the 
patient’s documents rather than on the patients themselves. A sample of the data 
collection form and coding scheme is found in Appendix 1. Data was collected on the 
following study variables as a result of a review of each patient’s medical and TB 
treatment records: 
 
Independent variables: Age, Gender, Initial patient weight in kilograms, Mother 
tongue, Date TB treatment commenced, Type of TB, Duration of the intensive phase, 
continuation phase and total phase of TB treatment, Treatment regimen, Number of 
medicines in the regimen, Stage of treatment, Concomitant medications, Co-morbidities 
and the Time to the onset of the main adverse event. 
 
Dependent (outcome) variable: Occurrence of adverse event (Yes or No). 
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Characterization of the dependent variable (adverse events): This entailed the 
further description of the adverse event(s) such as, for example, rash on the skin, the 
grading of the seriousness of adverse events, the duration of adverse events, actions 
taken to manage the adverse events, and the outcomes of the adverse events. 
 
Data analysis 
The researcher coded the data by using the basic scheme depicted on the data collection 
form in Appendix 1. The coded data was then single-entered into Epi Info, version 3.4.3 
(November 2007) for data management and statistical analysis. There being few records 
and manageable records (59), the researcher went through all data entered into the 
statistical software and verified the accuracy and completeness of data entry against the 
manual data collection forms. Any errors and discrepancies were investigated and 
rectified. Microsoft Excel® (2010) was then used to draw the charts. This approach is 
similar to that employed by Furin and colleagues (Furin et al., 2001) used Microsoft 
Excel for data entry and Epi Info 6.0 for statistical analysis in their study of the 
occurrence of serious adverse effects in patients receiving therapy for multi-drug 
resistant tuberculosis. Categorical data was coded either as mutually exclusive choices 
or multiple response choices or short descriptive text to facilitate computerized analysis. 
Continuous numerical data such as patient age and initial body weight were entered as 
numeric variables. The data was cleaned through visual checks on raw data set and by 
exploratory graphical analysis of the frequency distributions of the data in order to 
identify and correct any erroneous, strange, unusual or outlier values. 
 
Both descriptive and analytic statistical methods were performed on the collected data. 
Descriptive statistics were used to describe the frequencies and distributions of the 
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various variables studied. These were also used to determine the prevalence of the 
reported adverse effects of the second-line anti-TB chemotherapy. Measures of central 
tendency and dispersion such as mean and standard deviation (mean ± SD), and 
median and inter quartile range (IQR), were used to summarize and describe the data 
set for quantitative variables. The non-paired Student’s t-test for univariate analysis was 
used to compare the means of continuous variables, such as age, between two sub-
groups, such as gender. As recommended by Katzenellenbogen, Joubert and Abdool 
Karim, (1997), exploratory methods were first utilized to obtain a general picture of the 
information contained in the data set, including an impression of the type of frequency 
distribution of the data variables, before proceeding with the detailed analysis.  
 
Subsequently, statistical methods of examining associations between variables were 
used to analyze the nature and strength of associations between various risk factors and 
the occurrence of adverse events related to the administration of second-line anti-TB 
medicines to patients in the study sample. 
A series of cross-tabulations for the bivariate analysis of a potential risk factor and the 
occurrence of grouped or single adverse event were constructed. The researcher 
calculated the relative risks and/ or odds ratios from the contingency tables and the chi-
square statistic (2) or Fisher’s exact test. He also made use of the logistic regression 
models to calculate the Odds ratios for multiple risk factors, and used confidence 
intervals (95%) and p-values (p< 0.05) to determine the statistical significance of the 
calculated risk ratios. A similarly designed study by Mendes, Cordeiro and Burdmann, 
(2009) that assessed the prevalence and risk-factors for acute kidney injury in patients 
with polymyxin B, applied the chi-square statistic (2) or Fisher’s exact test and the non-
paired Student’s t-test for univariate analysis to compare the means of continuous 
variables. These investigators applied binary logistic regression for the analysis of risk-
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factors, since this regression model allows for the simultaneous analysis of more than 
one risk factor or independent variable. In this study, the researcher applied 
multivariate logistic regression analysis to examine the effect of multiple risk factors on 
the adverse event outcome of interest. 
 
Validity and bias 
Selection bias: Since all of the patients who were receiving treatment at the TB 
treatment facility during the study period were included in the sample, there was 
minimal risk of selection bias. No systematic differences in the selection or follow-up of 
patient records were observed by the researcher. 
 
Information bias: The facility TB treatment register and clinical records may have 
been completed with varying degrees of thoroughness and accuracy because of 
variations in clinician’s conscientiousness and attention to detail. This phenomenon was 
considered by the researcher to be random in nature, hence may have led to non-
differential information bias, which may have biased the risk estimates towards the 
null. The risk of information bias was therefore non-differential because the variation in 
the level of completion of patient treatment records was not related to the prior 
knowledge of the attending clinician with regard to specific drug exposures or the 
occurrence of specific adverse event(s).  
 
Because the varying lengths of time for which each patient had been receiving anti-TB 
treatment when the data was collected, there could have been a differential bias 
between patient exposure to specific anti-TB drugs and the risk of adverse events, 
which may have biased the risk estimates  either towards or away from the null. This 
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bias was adjusted for during multivariate analysis using length of time on treatment as 
a confounder.  
 
Lastly, the researcher performed no causality analysis on patient-reported adverse 
events, which could have served to introduce a misclassification bias as to whether the 
adverse event was due to a specific drug or not. 
 
Confounding: The researcher used stratification and multivariate analyses in the 
analysis stage to control for the measured, potential confounders.  
 
Stratification 
The following variables were used for stratification: HIV status, ARV use status, gender, 
diagnostic category of DR-TB (mono/poly drug-resistant TB; multi (extensively) drug-
resistant TB, prescription (use) of selected anti-TB medicines (such as, cycloserine), and 
the stage of treatment (intensive versus continuation phase). 
 
Multivariate analysis 
The researcher used more than one covariate during multivariate analysis to examine 
the effect of the introduction of other variables into the estimated risk measure (Odds 
ratio). For example, in analyzing the risk of joint pain caused by the use of cycloserine-
containing anti-TB regimens, the researcher applied a multivariable model that 
included age ≥45 years, female gender, the use of cycloserine, the use of kanamycin, the 
use of levofloxacin, HIV status, and a baseline body weight ≤ 45 kilograms. 
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Precision and Reliability: The same data collector and data collection tool was used 
to collect the required data so that variations in data would be minimized. It was, 
however, challenging for the researcher to determine the precise time when a particular 
adverse event had occurred.  
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5. ETHICAL CONSIDERATIONS 
 
This retrospective study involved the review of medical records of patients who were 
currently on treatment for drug-resistant tuberculosis, or those who had completed 
their treatment for drug-resistant tuberculosis. But since there was no direct interaction 
between the researcher and patients, there was no direct risk to the study subjects that 
arose because of the conduct of this study. The researcher abided by the following 
ethical principles during the design, the requests for the relevant approvals and during 
the conduct of the study:  
 
Anonymity: Specific patient identifiers were omitted from the study data set in order 
to guarantee the privacy of the individuals from whom the data was collected. In 
addition to this, the data was reported in a de-identified and an aggregate manner. 
 
Confidentiality: The researcher observed the utmost confidentiality during the 
conduct of the study. He protected the study data files from unauthorized access by 
using a password to gain controlled access, and locked raw data forms securely in a 
cupboard. The key to this cupboard was always kept by the researcher and by the 
researcher alone.   
 
Ethical clearance: Ethical approval for the study was obtained from the University of 
the Western Cape (UWC) Higher Degrees Committee, as well as from the Ministry of 
Health and Social Services (MoHSS) research unit (Appendix 2 and 3). 
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Study approval: The researcher sought permission to conduct this study from the 
Permanent Secretary, Ministry of Health and Social Services, Namibia (Appendix 3). 
  
Permission to collect data from the facility: The researcher sought formal 
permission to collect data from the patients’ treatment records at the study facility from 
the facility management by means of a letter addressed to the Principal Medical officer 
(Appendix 4 and 5). 
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6. RESULTS  
Descriptive analysis 
The flow diagram below summarizes the distribution of the 59 patients included in the 
study, according to their HIV status and antiretroviral treatment. 
 
 
Figure 6.1: Distribution of patients with drug-resistant tuberculosis, based on their HIV status and 
antiretroviral treatment (N=59) 
 
Fifty-nine patients were treated for DR-TB during the study period. There were more 
males (66%) than females in the sample. The mean age of the patients was 34.7 years 
(Table 4). The males in the sample were slightly older than the females (36.9 as against 
31 years respectively; p = 0.02). The mean baseline weight was 52.5 kilograms, with no 
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statistically significant gender difference (53.6 kgs-males, 49.8 kgs-females; p=0.23). 
About one-third of the patients were unemployed. 
 
 
Table 6.1: Some demographic characteristics of adults treated for DR-TB at the study site, 2008-2010 
Characteristic n (%)      N=59 
Gender  
Male 38 (64%) 
Female 20 (34%) 
Missing 1 (2%) 
Age (years) ± SD; median (IQR) 34.7 ± 9.4; 34 (27-42) 
Male 36.9 ± 8.4; 37.5 (31-42) 
Female 31.0 ± 10.2; 31 (24.5-37.5) 
Weight (kgs) ± SD; median (IQR) 52.5 ± 11.3; 52.3 (47-60) 
Male 53.6 ± 7.8; 54 (49.3-59.6) 
Female 49.8 ± 16.4; 45.6 (40.8-54.6) 
Occupation  
Unemployed 18 (31%) 
Employed   20 (34%) 
Student 1 (2%) 
Missing 20 (34%) 
SD = standard deviation; kgs = kilograms; IQR = interquartile range  
 
Table 6.2 shows that almost all (92%) the patients had a prior history of treatment with 
either first-line or second-line anti-tuberculosis medicines. Over three quarters (78%) of 
the 59 patients had been previously treated with first-line anti-tuberculosis medicines 
including isoniazid, rifampicin, ethambutol, pyrazinamide and streptomycin. 
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 Table 6.2: Clinical characteristics of the 59 patients treated for DR-TB at the study site, 2008-2010 
Characteristic n (%)  
Type of TB    
PTB smear + 55 (93%) 
PTB smear - 3 (5%) 
EPTB 1 (2%) 
Diagnostic category of DR-TB  
Previously treated with 1st line medicines 46 (78%) 
Previously treated with 2nd line medicines 8 (14%) 
New patient, never treated for TB 5 (8%) 
TB drug-resistance pattern  
MDR 36 (61%) 
Poly-resistant 18 (28%) 
XDR 1 (2%) 
Missing 4 (6%) 
TB = tuberculosis; PTB = pulmonary tuberculosis; + = positive; - = negative; EPTB = extra pulmonary 
tuberculosis; DR-TB = drug-resistant TB; MDR = multidrug-resistant; XDR = extensively drug-
resistant 
 
Table 6.3 shows that approximately half of the patients (31/59 or 53%) were co-infected 
with the human immunodeficiency virus (HIV). Of the 31 HIV co-infected DR-TB 
patients, 13 (42%) were being treated with highly active antiretroviral treatment 
(HAART).   
 
The MoHSS ART guidelines applied during the period covered by this study required 
the CD4 cell counts of less than 200 cells per cubic millimeter (cells/mm3) as part of the 
eligibility criteria for patients to be started on treatment (ART). Not all of the HIV-
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positive TB patients were therefore eligible for ART. This explains why the other 18 out 
of the 31 HIV-infected patients (58%) were not on ARVs. 
 
While all of the patients receiving anti-tuberculosis treatment were also receiving 
adjunctive pyridoxine treatment, all of the patients with an HIV-positive diagnosis were 
on cotrimoxazole prophylaxis treatment. 
 
Table 6.3: Treatment characteristics of the 59 patients treated for drug-resistant tuberculosis 
Characteristic n (%)  
Number of medicines in anti-TB regimen; median 
(range) 
 
Intensive phase regimens 5 (4-7) 
Continuation phase regimens 3 (3-5) 
Days on intensive phase treatment; Median (IQR) 
n=53 
 
Male 182 (154-186)  
Female 184 (165-211)  
Days on continuation phase treatment; Median (IQR) 
n=49 
 
Male 389 (185-503)  
Female 522 (451-584)  
HIV co-infection 31 (53%) 
Male 19 (32%) 
Female 12 (20%) 
Unknown 3 (5%) 
Proportion of HIV-positive persons on HAART* 13 (42%) 
D4T/3TC/EFV  5 (16%) 
AZT/3TC/EFV  3 (10%) 
AZT/3TC/NVP  2 (6%) 
TDF/3TC/EFV  2 (6%) 
D4T/3TC/NVP  1 (3%) 
* As percentage out of 31, which is the number of patients with HIV co-infection 
IQR = interquartile range; HIV = human immunodeficiency virus; HAART = highly active antiretroviral therapy; 
d4T = stavudine; AZT = zidovudine; 3TC = lamivudine; EFV = efavirenz; TDF = tenofovir disoproxil fumarate; 
NVP = nevirapine 
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Co-morbidities  
Apart from HIV infection, the other co-morbidities that the researcher found in the 
patient sample included diabetes mellitus (2 patients); asthma (1 patient); hypertension 
(1 patient), and psychiatric disease (1 patient). 
 
There were no reported cases of hepatic disease, peptic ulcer disease and renal disease. 
Being cognizant of the possibility of these co-morbidities right from the beginning of 
treatment is important because they could later be confused with drug-induced 
morbidity and may also influence the choice of specific regimens and dosages. This 
could confound the relationships between anti-TB drug exposure and the occurrence of 
an adverse event. 
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Distribution of the stages of treatment on the date of data collection  
At the time of data collection, about one-fifth of the 59 patients were still in the intensive 
phase of DR-TB treatment, while the majority of the patients (66%) were in the 
continuation phase of DR-TB treatment (Figure 6.2). 
 
 
Figure 6.2: Distribution of patients according to the stage of treatment (N=59) 
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Individualization of DR-TB treatment 
In the intensive phase of treatment, there were 30 unique regimens. This implied a high 
degree of individualized therapy of drug-resistant tuberculosis. Figure 6.3 shows that 
the three most commonly used regimens were:  
1. AMK/CPX/ EMB/ ETO/ PZA, (17%)  
2. EMB/ETO/ KM/ LFX/ PZA, (14%) 
3. CS/ EMB/ ETO/KM/LFX/ PZA, (11%) 
 
 
Figure 6.3: Distribution of DR-TB regimens used in the intensive phase of treatment  
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Figure 6.4: Distribution of DR-TB regimens used in the continuation phase of treatment 
 
There were 18 unique regimens used in the continuation phase of treatment of drug-
resistant tuberculosis. Figure 6.4 shows that the three most commonly used regimens 
were:  
1. CS/ ETO/ LFX, (27%)  
2. EMB/ ETO/ LFX, (21%) 
3. ETO/ LFX/ PZA, (13%) 
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Frequency of the use of specific second-line anti-TB medicines 
 
 
Figure 6.5: Frequency of the use of specific anti-TB medicines used for DR-TB treatment 
 
Fifteen different anti-tuberculosis medicines were used by the patients included in the 
study (Figure 6.5). Most of the patients were treated with regimens containing 
pyrazinamide (93%) and ethionamide (92%). All patients were treated with an injectable 
anti-tuberculous agent (aminoglycoside or aminopeptide) during the intensive phase of 
treatment, with kanamycin being the most frequently used aminoglycoside (54%). 
Fluoroquinolones were used in almost all (98%) of the patients. Of these, levofloxacin 
(66%) was used twice as much as ciprofloxacin (32%).  
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Occurrence of adverse events during the treatment of drug-resistant 
tuberculosis 
 
Fifty-three of the 59 patients experienced at least one adverse event, which is a 90% 
prevalence of adverse events. A total of 141 adverse events were reported by these 
patients. The number of adverse events experienced by an individual patient ranged 
from one to eight. The percentage of patients experiencing a given number of adverse 
events diminished between the intensive phase and the continuation phase of treatment 
(Figure 6.6).  Almost all (87%) of these 141 adverse events were experienced during the 
intensive phase of treatment as shown in Table 6.4. 
 
 
Figure 6.6: Frequency of number of adverse events per patient in the intensive and continuation phase 
of treatment 
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The average number of adverse events experienced by patients when using specific 
anti-tuberculosis medicines ranged from one to three. Patients who were on regimens 
that contained streptomycin, capreomycin, cycloserine and para-amino salicylic acid 
(PAS) experienced the highest average number of adverse events (3 adverse events per 
patient), while patients who were using amoxycillin/ clavulanic acid and clofazimine 
experienced the fewest, with an average of one adverse event per patient. The rest of the 
medicines were associated with a similar average number of two adverse events per 
patient (Figure 6.7). 
 
 
 
PAS= para amino salicylic acid  
Number next to a drug name indicates the mean adverse events experienced per patient 
treated with that drug 
Figure 6.7: Average number of adverse events experienced per patient exposed to specific anti-
tuberculosis drug 
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The three most frequently reported groups or specific types of adverse events were: 
ototoxicity (hearing loss and tinnitus), gastrointestinal tract (GIT)-related events and 
joint pain (Figure 6.8).  
 
 
Figure 6.8: Overall frequency of the main adverse events during DR-TB treatment 
 
The distribution of each type of adverse event between the intensive and continuation 
phases is shown in table 6.4. 
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Table 6.4: Frequency of adverse events by treatment phase in the 53 patients who reported 
experiencing at least one adverse  
Grouped 
adverse events 
Specific 
adverse events 
Both 
phases 
(N=53)* % 
Intensiv
e phase 
(N=53) % 
Continuatio
n phase  
(N=49) † % 
Hearing loss 
and Tinnitus Tinnitus 24 45% 21 40% 3 6% 
 
Diminished 
hearing 
capacity 13 25% 12 23% 1 2% 
 Sub-total 37 70% 33 62% 4 8% 
GIT-related Nausea 12 23% 8 15% 4 8% 
 
Abdominal 
pain 9 17% 8 15% 1 2% 
 Vomiting 6 11% 6 11% 0 0% 
 Diarrhea 5 9% 5 9% 0 0% 
 Constipation 2 4% 2 4% 0 0% 
 Sub-total 34 64% 29 55% 5 10% 
Others  Joint pain 15 28% 13 25% 2 4% 
 Headache 11 21% 10 19% 1 2% 
 Fatigue 10 19% 8 15% 2 4% 
 Dizziness 8 15% 7 13% 1 2% 
 Rash 7 13% 7 13% 0 0% 
 Neuropathy 4 8% 2 4% 2 4% 
 Fever 3 6% 3 6% 0 0% 
 Vision changes 3 6% 2 4% 1 2% 
 Depression 2 4% 2 4% 0 0% 
 Psychosis 2 4% 2 4% 0 0% 
 Severe hepatitis 1 2% 1 2% 0 0% 
 
Decreased 
urine 1 2% 1 2% 0 0% 
 Anemia 2 4% 2 4% 0 0% 
 
Loss of libido, 
delayed 
ejaculation 1 2% 0 0% 1 2% 
Total of all adverse events 141  122  19  
Percent of all adverse events 100%  87%  13%  
*53 of the 59 patients reported experiencing at least one DR-TB treatment-related adverse event and 76% of the 53 
patients had either completed or were still in the intensive phase of treatment at the time of data collection. †49 of 
the patients had progressed into the continuation phase of treatment and were either still in the continuation 
phase treatment or had completed treatment at the time of data collection. % = percent. The sum of column 
percentages may exceed 100% because a patient may experience more than one adverse event.  GIT = 
gastrointestinal tract. 
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Differences in the prevalence of adverse events in HIV-infected and HIV un-
infected patients 
Five adverse events were more common among HIV-infected patients than among HIV-
negative patients (the figure in bracket shows the excess frequency or the difference in 
absolute percentage frequency of adverse events between HIV-infected and HIV- 
uninfected patients): abdominal pains (22%); rash (16%); nausea (10%); diminished 
hearing capacity (7%), and joint pain (6%). By contrast, fever and fatigue are examples 
of adverse events that were reported less frequently by these patients (Figure 6.9). 
 
 
AE = adverse event; HIV = human immunodeficiency virus; DR-TB = drug-resistant tuberculosis 
Figure 6.9: Comparison of the differences in the prevalence of adverse events in HIV-positive and 
HIV-negative DR-TB patients 
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While 73% of the moderate-to-severe adverse events lasted for more than 3 months, 
60% of mild adverse events resolved themselves within 3 months of onset. Overall, in 
53% of patients, the adverse events resolved within 3 months of onset, while 47% of 
patients experienced adverse events that persisted beyond 3 months. Adverse events 
were severe and warranted discontinuation of the suspected offending medicine in 4 
out of 26 (15%) patients. Four out of the 42 (9%) patients for whom data was available 
recovered from their adverse reactions with sequelae (long-term medical complication). 
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Risk factor analysis 
In this section, the findings of risk factor analysis are presented. Figure 6.10 is a flow 
chart that depicts how the researcher performed the sub-group analysis during risk 
factor analysis.  
 
 
 
 
*Two (2) of the MDR-TB patients had unknown HIV status. 
Figure 6.10: Sub-groups of DR-TB patients by type of DR-TB, HIV status and ARV use 
 
 
 
 
DR-TB 
(n = 59) 
MDR-TB 
(n = 37)* 
Mono- and Poly-Resistant TB 
(n = 18) 
Missing Data 
(N = 4) 
HIV Negative 
(n = 18) 
HIV Positive 
(n = 17) 
HIV Negative 
(n = 7) 
HIV Positive    
(n = 11) 
On ARVs         
(n = 5) 
Not on ARVs  
(n = 6) 
On ARVs         
(n = 7) 
Not on ARVs  
(n = 10) 
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The researcher assessed the following seven risk factors for their influence on the 
occurrence of those general and specific adverse events that were associated with use of 
second-line anti-TB medicines:   
1. Length of time on DR-TB treatment 
2. HIV co-infection 
3. ARV co-medication 
4. Specific anti-TB medicines 
5. Age 
6. Gender 
7. Baseline body weight 
 
Risk factor analysis in all forms of DR-TB 
The likelihood of occurrence of any adverse event, irrespective of its severity grading, 
was highest within the first two weeks of DR-TB treatment (OR 11.8; CI 1.3 - 104.7, p= 
0.03), (Table 6.5).  
Moderate-to-severe adverse events occurred mostly after 4 weeks of DR-TB treatment 
or after a much longer period of time (OR 6.4; CI 1.6 – 25.6, p=0.01). These adverse 
events were significantly associated with the presence of HIV co-infection (OR 3.1; 1.0 – 
9.3; 0.04), (Table 6.5). 
Adverse events lasting for more than 3 months occurred mostly after 4 weeks of 
treatment or after a much longer period of time (OR 9.6; CI 1.8 – 52.2, p=0.01), and were 
highest in patients co-infected with HIV (OR 3.9; CI 1.2 – 13.6, p=0.03) –particularly 
those patients on anti-retroviral co-medication  (OR 7.9; 1.1 – 56.1, p=0.04). These long-
lasting adverse events were also mostly associated with the use of ciprofloxacin-based 
DR-TB regimens (OR 4.0; CI 1.1 – 14.6, p=0.04), (Table 6.5). 
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On the other hand, adverse events that lasted for 3 months or less were mostly 
encountered within the first 4 weeks of DR-TB treatment (OR 5.9; CI 1.5 – 23.2, p=0.01). 
These short-duration adverse events were mostly associated with the use of 
levofloxacin-based regimens during treatment of DR-TB (OR 5.9; CI 1.6 – 21.5, p=0.01), 
(Table 6.5). 
 
With regard to specific adverse events as shown in Table 6.6, the occurrence of fatigue 
was highest among young adults who were younger than 25 years old (OR 5.9; CI 1.2 – 
28.1, p= 0.03). Gastrointestinal tract (GIT)-related adverse effects were mostly reported 
within the first 4 weeks of DR-TB treatment (OR 4.3; CI 1.3 – 14.7, p=0.02). The 
occurrence of nausea was significantly associated with the use of zidovudine (AZT)-
based Highly Active Antiretroviral Therapy (HAART) (OR 7.5; CI 1.1 – 51.5, p= 0.04). 
Hearing loss and tinnitus were encountered particularly after 3 months of DR-TB 
treatment (OR 3.6; CI 1.1 – 12.3, p=0.04). Joint pains were significantly associated with 
the use of cycloserine-based regimens (OR 6.4; CI 1.6 – 25.8, p=0.01), while the risk of 
rash was significantly associated with the female gender (OR 15.9; CI 1.8 – 143.7, 
p=0.01).  
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Table 6.5: Risk factors for general adverse events in all 59 DR TB patients 
Adverse event Risk Factor Odds Ratio 
(OR) 
95% CI p value 
Any adverse event Treatment duration of ≤ 2 
weeks 
11.8 1.3 - 104.7 0.03* 
     
     
Moderate-severe 
adverse events 
Treatment duration of ≥ 4 
weeks 
6.4 1.6 - 25.6 0.01* 
 HIV co-infection 3.1 1.0 - 9.3 0.04* 
     
Adverse events 
lasting > 3 months 
Treatment duration of ≥ 4 
weeks 
9.6 1.8 - 52.2 0.01* 
 HIV co-infection 3.9 1.2 - 13.6 0.03* 
 ARV co-medication 7.9 1.1 - 56.1 0.04* 
 Ciprofloxacin-based regimens 4.0 1.1 - 14.6 0.04* 
     
Adverse events 
lasting ≤ 3 months 
Treatment duration of ≤ 4 
weeks 
5.9 1.5 - 23.2 0.01* 
 Levofloxacin-based regimens 5.9 1.6 - 21.5 0.01* 
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Table 6.6: Risk factors for specific adverse events in all 59 DR TB patients 
Adverse event Risk Factor Odds Ratio 
(OR) 
95% CI p value 
     
Fatigue Age ≤ 25 years 5.9 1.2 - 28.1 0.03* 
     
GIT adverse effects Treatment duration of ≤ 4 
weeks 
4.3 1.3 - 14.7 0.02* 
Nausea AZT-based HAART 7.5 1.1 - 51.5 0.04* 
Hearing loss and 
Tinnitus 
Adverse events lasting > 3 
months 
3.6 1.1 - 12.3 0.04* 
     
Joint pain Cycloserine-based regimens 6.4 1.6 - 25.8 0.01* 
     
Rash Female  15.9 1.8 - 143.7 0.01* 
 
 
 
Risk factor analysis in a sub-group of MDR-TB cases (n=37) 
Among patients with MDR-TB (as shown in Table 6.7), HIV co-infection was more 
likely to be associated with a higher risk experiencing 3 or more adverse events (OR 8.0; 
CI 1.3 – 50.0, p=0.03).  The risk of experiencing moderate-to-severe adverse events was 
even more pronounced in this sub-group of patients (OR 10.4; CI 1.6 – 66.9, p=0.02) as 
compared to the entire sample of 59 patients (OR 3.1; CI 1.0 – 9.3, p=0.04). These 3 or 
more adverse events were predominantly of a moderate-to-severe nature (OR 4.3; CI 1.1 
– 17.4, p=0.04). The association of joint pain and use of cycloserine-containing anti-TB 
regimens maintained statistical significance in this sub-group of MDR-TB patients (OR 
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8.9; CI 1.6 – 49.8, p=0.01) and was higher than for the entire patient sample (OR 6.4; CI 
1.6 – 25.8, p=0.01). 
 
 The risk of joint pain associated with the use of cycloserine-based MDR-TB regimens 
was even more pronounced among female HIV-positive patients who were using 
antiretroviral medication (OR 22.7; CI 2.2 – 237.4, p=0.01), (Table 6.8). 
 
The concomitant use of cycloserine-based anti-TB therapy and efavirenz-based HAART 
were both statistically significant independent risk-factors for experiencing joint pain 
among patients with MDR-TB (Cycloserine: OR 15.7; CI 1.7 – 144.4, p=0.15; Efavirenz: 
OR 13.5; CI 1.0 – 178.3, p = 0.048), (Table 6.8). 
 
Table 6.7: Univariate risk factor analysis in a sub-group of 37 patients with MDR-TB 
Adverse event Risk Factor Odds Ratio 
(OR) 
95% CI p value 
3 ≥ adverse events HIV co-infection 8.0 1.3 – 50.0 0.03* 
 ARV co-medication 0.2 0.0 – 1.6 0.13 
 Moderate-severe adverse 
events 
4.3 1.1 – 17.4 0.04* 
Moderate-severe 
adverse events 
HIV co-infection 10.4 1.6 - 66.9 0.02* 
Joint pain Cycloserine-based regimens 8.9 1.6 - 49.8 0.01* 
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Table 6.8: Multivariate risk factor analysis in a sub-group of 37 patients with MDR-TB 
Adverse event Risk Factor Odds Ratio 
(OR) 
95% CI p value 
3 ≥ adverse events HIV co-infection 5.3 1.0 – 27.8 0.047* 
 Efavirenz-based HAART 0.4 0.1 – 3.0 0.36 
     
     
Moderate-severe 
adverse events 
HIV co-infection 6.9 1.3 - 37.2 0.02* 
 Efavirenz-based HAART 0.2 0.0 – 1.6 0.13 
 Stavudine-based HAART 0.2 0.1 – 1.9 0.14 
     
Joint pain Cycloserine-based regimens 15.7 1.7 - 144.4 0.015* 
 Efavirenz-based HAART 13.5 1.0 – 178.3 0.048* 
     
Joint pain Cycloserine-based regimens 22.7 2.2 - 237.4 0.01* 
 HIV co-infection 3.4 0.4 – 27.5 0.26 
 ARV co-medication 4.4 0. 3 – 68.7 0.30 
 Female gender 1.1 0.2 – 6.6 0.95 
 
 
Risk factor analysis in a sub-group of patients with mono- and poly-resistant 
TB (n=18) 
The risk of experiencing moderate-to-severe adverse events was significantly associated 
with the use of ciprofloxacin-based anti-TB regimens (OR 16; CI 1.3 – 194.6, p= 0.03). 
These moderate-to-severe adverse events were hearing loss and tinnitus (OR 28.0; CI 2.1 
– 378.9, p=0.01), in both HIV-positive and HIV-negative patients (Table 6.9). 
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Having a low baseline body weight (≤ 45 kgs) was a predisposing factor for decreased 
hearing (OR 36; CI 1.7 – 756, p=0.02) and gastrointestinal tract-related adverse events 
(OR 16.5; CI 1.1 – 250.2, p= 0.04) in patients who were being treated for mono- and poly-
resistant tuberculosis (Table 6.9). 
 
Ototoxicity (hearing loss and tinnitus) was significantly associated with the use of 
amikacin-based (OR 12.0; CI 1.3 – 111.3, p=0.03) as well as ciprofloxacin-based anti-TB 
regimens (OR 27.0; CI 1.9 – 368.2, p= 0.01).  In addition, the use of ciprofloxacin-based 
anti-TB regimens was independently associated with the occurrence of tinnitus (OR 
13.33; CI 1.1 – 169.4, p=0.04), (Table 6.9).  
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Table 6.9: Univariate risk factor analysis in a sub-group of 18 patients with mono- and poly-resistant 
DR-TB 
Adverse event Risk Factor Odds Ratio 
(OR) 
95% CI p value 
Moderate-severe 
adverse events 
Ciprofloxacin-based regimens 16.0 1.3 – 194.6 0.03* 
     
GIT-related 
adverse events 
Baseline body weight ≤ 45 kgs 16.5 1.1 -- 250.2 0.04* 
     
Decreased hearing Baseline body weight ≤ 45 kgs 36.0 1.7 – 756.0 0.02* 
     
Hearing loss and 
Tinnitus 
Amikacin-based regimens 12.0 1.3 – 111.3 0.03* 
 Ciprofloxacin-based regimens 27.0 1.9 – 368.3 0.01* 
     
Tinnitus Amikacin-based regimens 9.0 0. 8 – 108.3 0.08 
 Ciprofloxacin-based regimens 13.3 1. 1 – 169.4 0.04* 
     
Hearing loss and 
Tinnitus 
Moderate-severe adverse 
events 
28.0 2.1 – 378.9 0.01* 
     
 
 
It is notable in Table 6.10 that the risk of decreased hearing in patients treated for mono- 
and poly-resistant tuberculosis was maintained in the multivariate logistic regression 
model that include the streptomycin as a covariate in the model (OR 33; CI 1.5 – 709, 
p=0.03). Note the instability and broadness of the confidence intervals, due to the small 
sample size.  
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Table 6.10: Multivariate risk factor analysis in a sub-group of 18 patients with mono- and poly-
resistant DR-TB 
Adverse event Risk Factor Odds Ratio 
(OR) 
95% CI p value 
Decreased hearing Baseline body weight ≤ 45 kgs 33.0 1.5 – 709.0 0.03* 
 Streptomycin 2.3 0.0 – 157.8 0.70 
     
Fatigue Baseline body weight ≤ 45 kgs 18.2 0. 6 - 512.9 0.09 
 Age ≤ 25 years 6.4 0. 4 - 116.6 0.21 
 Male Gender 2.8 0.2 – 53.6 0.49 
 Isoniazid-based anti-TB 
regimens 
11.8 0.3 – 531.9 0.20 
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Table 6.11: Comparison of key risk factors between patients with mono- and poly-resistant TB and 
MDR-TB 
Mono - and poly-resistant TB MDR-TB 
 Low baseline body weight (≤45 kgs) associated with 
increased risk of GIT-related adverse events and 
decreased hearing 
 HIV co-infected individuals associated 
with increased risk of 3 ≥ adverse 
events and moderate-severe adverse 
events 
 Amikacin and Ciprofloxacin-based anti-TB 
regimens associated with an increased risk of 
ototoxicity 
 Cycloserine-based anti-TB regimens 
and Efavirenz-based HAART 
associated with increased risk of joint 
pain 
 
 
Comparison of key risk factors for selected adverse events between HIV-
infected and HIV-uninfected patients 
 
The statistical significance of the association between joint pain and the use of 
cycloserine-based anti-TB regimens was maintained in a sub-group of HIV-infected 
patients (OR 7.5; CI 1.2 – 45.8, p=0.03). This association, however, lost its statistical 
significance among HIV-uninfected patients (7.5; CI 0.7 – 76.7, p=0.09), (Table 15).  
 
The finding that hearing loss and tinnitus (ototoxicity) was of a moderate-to-severe 
nature in a statistically significant manner was maintained in both HIV-infected (OR 
8.7; CI 1.7 – 45.2) and HIV-negative patients (OR 7.8; 1.2 – 52.3, p=0.03), (Table 6.12). 
 
Note in Table 6.12 that HIV status is an effect-modifier for the association between the 
use of cycloserine-based DR-TB regimens and the occurrence of gastrointestinal tract-
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related adverse events because the odds ratios for the HIV-positive and HIV-negative 
status are clearly different. 
 
HIV status is a confounder for the relationship between the use of cycloserine-based 
DR-TB regimens and the occurrence of joint pains because the odds ratios are similar in 
both strata of HIV-infected and HIV-uninfected DR-TB patients.  
 
In the same way, HIV status confounds the relationship between moderate-to-severe 
adverse events being caused by ototoxicity (hearing loss and tinnitus) because the odds 
ratios are similar in both strata of HIV status. 
 
Table 6.12: Comparison of key risk factors between HIV-positive and HIV-negative DR-TB patients 
HIV positive HIV negative 
Adverse events OR 95 CI 
p 
value Adverse events OR 95 CI 
p 
value 
GIT-related Adverse 
events    
GIT-related 
Adverse events    
Cycloserine 1.1 0.3 - 4.6 0.87 Cycloserine 10.3 1.0 - 103.7 0.048* 
        
Nausea    Nausea    
Adverse events 
lasting < 1 month 21.3 1.7 - 263.7 0.02* 
Adverse events  
< 1 month cannot be calculated.  
        
Joint pain    Joint pain    
Cycloserine 7.5 1.2 - 45.8 0.03* Cycloserine 7.5 0.7 - 76.7 0.09 
        
Hearing 
loss/Tinnitus    Hearing loss/Tinnitus   
Moderate-severe 8.7 1.7 - 45.2 0.01* Moderate-severe 7.8 1.2 - 52.3 0.03* 
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7. DISCUSSION  
Prevalence of adverse events during treatment of drug-resistant 
tuberculosis 
Adverse events, notably tinnitus, hearing loss, GIT-related adverse events and joint 
pains, were experienced by most (90%) of the patients included in the study.  Most of 
the adverse events were reported in the intensive phase of treatment. Some differences 
in the occurrence of adverse events were observed in HIV-positive and HIV-negative 
patients respectively. Abdominal pain, rash, nausea, and decreased hearing and joint 
pain were among the adverse events more frequently reported by HIV-positive 
patients, whereas fever and fatigue were reported relatively less frequently (that is, they 
were reported most frequently among HIV-uninfected patients who were being treated 
for drug-resistant tuberculosis). 
 
The 90% prevalence of adverse events in this study is higher than it is in other reported 
studies, where it ranged from 69%-86% (Nathanson, Gupta, Huamani et al., 2005; Bloss, 
Kuksa, Holtz et al., 2010; Seung, Omatayo, Keshavjee et al., 2009), but was lower than the 
96% prevalence reported by Tupasi et al. in their study of 117 patients that was 
conducted in the Philippines (Tupasi, Gupta, Quelapio et al., 2009). While the reasons 
for this heterogeneity in the prevalence of adverse events related to DR-TB 
chemotherapy is unclear, it might be related to a variation in the use of specific anti-TB 
agents as well as in differences in co-morbidities and other covariates between study 
settings. The patient sample in this study is similar to those in other studies in terms of 
patient demographics, the number of second-line anti-TB medicines being used and the 
duration of treatment. In addition, treatment has proceeded in accordance with 
recommended guidelines (MoHSS, 2006, and WHO, 2010a). The HIV co-infection rate 
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and specific anti-TB agents used may however differ between settings. This should be 
borne in mind when interpreting and comparing results of adverse events reported 
from different countries. While this study’s finding on the TB/HIV co-infection rate is 
higher than that reported in Europe and South East Asia where HIV prevalence rates 
are low (Leimane, Riekstina, Holtz et al., 2005; Lanternier, Dalban, Perez et al., 2007 and 
Cain, Kanara, Laserson et al., 2007), it is lower than the 80% co-infection rate observed 
for Lesotho, a country in Southern Africa with a very high prevalence rate of HIV 
infection (Seung, Omatayo, Keshavjee et al., 2009). 
 
The frequency of tinnitus (45%) in the present study was higher than the 5.1%-24% 
range reported in the literature (Nathanson, Gupta, Huamani et al., 2005; Bloss, Kuksa, 
Holtz, et al., 2010; Tupasi, Gupta, Quelapio et al., 2009). The frequency of loss of hearing 
(25%) was within the range of 6.7%-33% that was reported in the literature (Tahaoglu, 
Torun, Sevim et al., 2001; Furin, Mitnick, Shin et al., 200); Bloss, Kuksa, Holtz et al., 2010; 
Tupasi, Gupta, Quelapio et al., 2009). The literature review shows that the reported rates 
of ototoxicity ranged from between 12% and 42% (Leimane, Riekstina, Holtz et al., 2005; 
Torun, Gungor, Ozmen et al., 2005; Seung, Omatayo, Keshavjee et al., 2009). This study 
found an almost double rate of ototoxicity in comparison to the 36% reported by Seung, 
Omatayo, Keshavjee et al., (2009), whose study population demographics, HIV 
prevalence and TB/HIV co-infection rates (although Lesotho’s TB/HIV co-infection rates 
are generally higher than for this study population) were fairly comparable to this 
study’s population. While it is still unclear as to why this should be so, one possible 
reason could be that the majority of the patients in the Seung study were still in the 
early stages of treatment, hence were exposed to relatively short periods of time to 
second-line anti-tuberculosis therapy (median of 252 days on treatment as compared to 
a median of 477 days for this study). Thus, not all of the potential adverse events may 
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have manifested at the time when they conducted and concluded their study. The high 
degree of heterogeneity of otological adverse events noted in the literature could have 
been brought about by differences in the use of specific ototoxic anti-TB medicines, 
varying exposure to other ototoxic medicines and environmental agents such as noise, 
as well as by the differences in the profiles of co-morbidities in the various patient 
population groups in the various studies. 
 
Ototoxicity due to second-line anti-tuberculosis medicines 
Ototoxicity (tinnitus and decreased hearing) is mainly associated with the use of 
parenteral anti-tuberculous agents, i.e. aminoglycosides and aminopeptides (Brummett 
and Fox, 1989; Nadol, 1993; de Jager and van Altena, 2002; Tan, Mulheran, Knox and 
Smyth, 2003; Duggal and Sarkar, 2007; and Selimoglu, 2007).  
 
The drug-specific rate of patient-reported tinnitus in this study ranged from 33%- 50%, 
while loss of hearing function was 13%-67%. These findings are above the range of 
15.4%-33% reported in studies conducted elsewhere (Tahaoglu, Torun, Sevim et al., 
2001; de Jager and van Altena, 2002; and Duggal and Sarkar, 2007).  
 
The high rates of tinnitus and loss of hearing function found in this study might be 
attributable to the fact that none of the audiometry readings were validated by a 
qualified audiologist or a specialist Ear Nose and Throat (ENT) surgeon 
(Otorhinolaryngologist). In addition to this, there might have been some additive effects 
of interaction with other concomitant and potentially ototoxic anti-TB drugs that were 
used in the anti-TB regimens, such as fluoroquinolones and cycloserine. There is, 
moreover, the possibility of the interactive effects that arise from the presence of HIV 
disease and the concomitant use of antiretroviral medicines such as nucleoside reverse 
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transcriptase inhibitors (like zidovudine), which may also have contributed to this high 
rate of ototoxicity (Schouten, Lockhart, Rees, Collier and Marra, 2006; Katijah, 2010). All 
of these factors need further investigation so that the exact nature of these interactive 
effects can be determined.  
 
Gastrointestinal tract-related adverse events during treatment of drug-resistant 
tuberculosis 
Gastrointestinal tract (GIT)-related adverse events (64%) were the second most recorded 
group of adverse events. The specific adverse events that were recorded were: nausea 
(23%), abdominal pain (17%), vomiting (11%), diarrhea 9%, and constipation (4%).  
 
The frequency of these specific GIT-related adverse events fall within the broad range 
reported in the literature (10.8%- 100%) (Furin, Mitnick, Shin et al., 2001; Nathanson, 
Gupta, Huamani et al., 2005; Leimane, Riekstina, Holtz et al., 2005; Torun, Gungor, 
Ozmen et al., 2005; Bloss E, Kuksa L, Holtz T H et al., 2010; Tupasi, Gupta, Quelapio et 
al., 2006; and Seung, Omatayo, Keshavjee, Furin, Farmer, and Satti, 2009). Since some 
studies have reported higher rates of specific GIT-related adverse events, it is possible 
that the patients in this study may have under-reported these adverse events during the 
course of their treatment.  
 
Joint pain (arthralgia) during treatment of drug-resistant tuberculosis 
Joint pain (28%) was the third most commonly reported adverse event. The findings of 
this study fall within (but more towards the upper side) the 6.7%-31% range that was 
reported in the literature (Torun, Gungor, Ozmen, et al.2005; Furin, Mitnick, Shin et al., 
2001; Bloss E, Kuksa L, Holtz T H et al., 2010; and Tupasi, Gupta, Quelapio et al., 2006).  
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The variations in the reported occurrence could be attributed to the fact that the joint 
pains (arthralgia) were either reported ungraded (regardless of their severity grading, 
as was the case in this study), or else they were separately reported according to their 
severity grading for mild and severe joint pains – as was the case in the research 
conducted by Tupasi, Gupta, Quelapio et al., (2006). 
 
Differences in the prevalence of adverse events in HIV-infected and HIV-uninfected 
persons treated for drug-resistant tuberculosis 
The frequency of abdominal pains, nausea, rash, decreases in hearing function and joint 
pain was higher in patients with HIV co-infection. This observation is consistent with 
that cited in Lanternier, Dalban, Perez, Bricaire, Costagliola and Caumes (2007), who 
found the risk of adverse events was higher in TB patients co-infected with HIV (OR 3.9 
95% CI 2.1 – 7.5, p< 0.001).  
 
However, because of the descriptive design of this study, the researcher was unable to 
establish and conclude associations from these relative adverse event frequencies in DR-
TB patients co-infected with HIV. The researcher therefore proposes an appropriate 
analytic design to further elucidate these identified associations.  
 
It was necessary for the researcher to consider the possibility of drug-drug interactions 
(Papastavros, Dolovich and Holbrook, 2002), drug-disease interactions, and disease-
disease interactions in the present study, particularly since an average of 5 different 
anti-TB agents were used by each patient in the study and that over 50% of the patients 
were co-infected with HIV (42% of these HIV co-infected patients were on additional 
antiretroviral medications).  
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Impact of adverse events on the continuity of treatment of drug-resistant tuberculosis 
In this study, the researcher found that in 15% of the patients, the adverse events were 
so severe that they warranted the discontinuation of the suspected offending medicine. 
This rate of this discontinuation is lower than that reported in the literature (Nathanson, 
Gupta, Huamani et al., 2005; Tahaoglu, Torun, Sevim et al., 2001; Shin, Pasechnikov, 
Gelmanova et al., 2007; and Bloss E, Kuksa L, Holtz T H et al., 2010).  
 
This study’s findings are nevertheless similar to those of Furin, Mitnick, Shin, et al. 
(2001), namely that because the patient was able to tolerate and bear the adverse events 
of the anti-TB medicines, these specific adverse events did not cause any 
discontinuation of the treatment apart from the occasional suspension of an offending 
agent in 11.7% of the patients. 
 
Risk-factors for the occurrence of adverse events during treatment of 
drug-resistant tuberculosis 
The researcher examined several risk factors in this study. This section provides an in-
depth discussion of the main findings about the risk-factors that were associated with 
the occurrence of adverse events in patients on DR-TB treatment, in the context of the 
available body of knowledge. 
 
Length of time on DR-TB treatment 
The first two weeks of DR-TB treatment were associated with the highest risk of an 
occurrence of any adverse event, while moderate-to-severe adverse events were mostly 
experienced after 4 weeks of DR-TB treatment. 
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These findings are consistent with those reported by Sharma, Mohan and Kadhiravan  
(2005), who found that the majority of adverse events experienced during treatment of 
DR-TB occurred within the first 2 months (or 8 weeks) of treatment. 
 
HIV co-infection and increased risk of serious or moderate-to-severe adverse events 
in the treatment of MDR-TB 
In this study, the researcher found that DR-TB patients, who were co-infected with HIV, 
had a higher risk of experiencing three or more adverse events, most of which were 
moderate-to-severe in nature. This finding is already reported in the literature. 
Marks and his colleagues found that, in a South African population of tuberculosis 
patients co-infected with HIV, serious adverse events (SAEs) during anti-tuberculosis 
therapy occurred more frequently in HIV co-infected patients than they did in HIV-
uninfected patients (26.7% versus 13.3% p=0.003) (Marks, Dheda, Dawson, Ainslie and 
Miller, 2009).  Similarly, the study conducted by Breen, Miller, Gorsuch, Smith, 
Schwenk, Holmes et al., (2006) found that serious adverse events occurred more 
frequently in TB patients who were co-infected with HIV (40% serious adverse reactions 
in HIV-positive patients versus 26% in HIV-negative patients, p=0.008). 
In addition to this, Sharma and colleagues noted that HIV-positive persons are more 
prone to anti-TB treatment-related adverse events and the risk of an increased 
possibility of adverse events with the presence of advanced immune suppression 
(Sharma, Mohan and Kadhiravan, 2005).  Other studies that have reported similar 
findings are those undertaken by Cohen and Meintjes (2010) and Abex, Varella, 
Siqueira, and Mello (2010). 
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ARV co-medication and the risk of serious or severe adverse events during DR-TB 
treatment 
This study found that HIV-infected DR-TB patients who were concomitantly treated 
with antiretroviral medication (and particularly with efavirenz-based HAART) were at 
an increased risk of experiencing moderate-to-severe adverse events. What is most 
notable is that there seems to be an interactive effect that increases the risk of joint pains 
among patients who are concomitantly being treated with efavirenz-based HAART and 
cycloserine-based DR-TB treatment regimens.  
Whereas the concomitant use of antiretroviral and anti-tuberculosis medications is 
known to be associated with an increased risk of occurrence of serious, treatment-
related adverse events (Venkatesh, Swaminathan, Andrews and Mayer, 2011), the 
researcher was unable to identify any study that specifically reported an association 
between increased joint pains (arthralgia) in patients who were being treated for HIV 
with efavirenz-based HAART.  
However, according to an online data base maintained by eHealthMe that tracks and 
analyses medication-related adverse events, 1.72% of the 5,276 people who reported 
experiencing side effects while taking efavirenz-based HAART had arthralgia, as of 
June 07, 2011 (eHealthMe, 2011).  
This association is further corroborated by a post-marketing follow-up reported by 
Merck Sharp and Dohme (MSD), the original innovators and manufacturers of 
efavirenz (MSD, 2006). Because post-marketing medicine safety data are reported 
voluntarily from a population of unknown size, accurate estimates of the prevalence 
and the risks of occurrence of the reported adverse events cannot be made. 
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Zidovudine-based HAART and the risk of nausea during DR-TB treatment 
There was an increased risk of nausea (which lasted less than a month) among patients 
treated for drug-resistant tuberculosis and who were concomitantly treated for HIV 
infection using zidovudine-based HAART.  
 
This finding is not new because zidovudine (AZT) is known to cause nausea, and this 
particular association has been extensively described in the literature. In the 
randomized clinical trial conducted by Spruance, Pavia, Mellors, Murphy, Gathe, Stool 
et al., (1997), nausea and vomiting were more common in patients who were receiving 
zidovudine than they were among patients receiving stavudine. This association has 
also been reported by Carr and Cooper (2000). 
 
Young adult age (≤ 25 years) and risk of fatigue in DR-TB treatment 
In this study, the risk of fatigue was found to be highest among young adults who were 
25 years old or younger.  
 
The researcher found no data available in the literature consistent with this finding, 
among patients being treated for DR-TB. The available evidence, which is based on 
first-line anti-tuberculosis drug regimens, was not specific for the association of patient 
age and fatigue. It indicated, instead, that the overall risk of adverse events increases 
among elderly persons who are over 60 years old (adjusted hazard ratio, 2.9; 95% CI, 1.3 
to 6.3, Yee, Pelletier, Parisien, Rocher and Menzies, 2003).  
 
Among 1,317 patients on first-line anti-tuberculosis treatment, the frequency of drug 
reactions increased from 2.3% at ages 0–19 to 4.6% at ages 20–39, 7.1% for ages 40–59 
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and to 8.4% for those who were 60 years old and above (Ormerod and Horsfield, 1996). 
The clinical significance of this finding is therefore unclear, and could have been a 
spurious statistical finding with no underlying biologically plausible explanation. 
 
Female gender and the risk of skin rash in DR-TB treatment 
The females in the sample were found to be at a higher risk of experiencing skin rash. 
No data was available from the reviewed literature that indicated a specific association 
between female gender and the risk of skin rash in patients who were being treated for 
drug-resistant tuberculosis.  
There were, however, various studies that reported that females, in particular, were at 
risk for the occurrence of adverse events of any kind among patients on both first-line 
and second-line anti-tuberculosis treatment. Being female was associated with an 
increased risk (OR = 1.6, 95%CI: 1.9–36.4) of experiencing an adverse event in patients 
being treated for pulmonary tuberculosis, irrespective of the type of drug-resistance of 
the infecting tubercle bacilli (Javadi, Shalviri, Gholami, Salamzedeh, Maghooli and 
Missaeedi, 2007).  
There is therefore a need for future research to verify the finding that there is an 
increased risk of skin rash for females, during treatment of drug-resistant tuberculosis 
using second-line anti-tuberculosis treatment.  
 
Low baseline body weight and the risk of adverse events during DR-TB treatment 
This study found that patients with a low body weight (≤45 kilograms) at the start of 
DR-TB treatment (i.e. underweight adults) in the sub-group of patients being treated for 
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mono- and poly drug-resistant M. tuberculosis, were associated with an increased risk of 
experiencing decreased hearing and GIT-related adverse events. 
However, few of the reviewed studies have reported findings based on patient body 
weight. In the study that was conducted by Kigen, Kimaiyo, Nyandiko, Faragher, Sang, 
Jakait, et al. (2011), baseline body weight was reported as a risk-factor for an increased 
risk of clinically significant drug-drug interactions in patients on antiretroviral therapy.  
The majority of other relevant studies have used the body mass index instead of patient 
body weight. None of the reviewed patient records in this study contained information 
on patient height because this measurement is not routinely taken at the study site. The 
researcher, therefore, was unable to calculate the body mass index for risk factor 
analysis for this study, and for comparison with other studies.  
 
Cycloserine-based anti-tuberculosis regimens and risk of joint pain (arthralgia) 
during DR-TB treatment 
According to data for this study, the use of cycloserine-based anti-TB regimens was 
associated with an increased risk of joint pain (arthralgia).  
There was no study in the literature that specifically reported an association between 
the use of cycloserine (either alone or as part of an anti-tuberculosis regimen) and 
occurrence of joint pain. Almost all of the reviewed relevant studies and reports 
highlighted the occurrence of adverse neuropsychiatric events that are associated with 
the use of cycloserine (Weyer, 2005; Arbex, Varella, de Siqueira and de Mello, 2010). 
On the other hand, pyrazinamide and fluoroquinolones are two types of second-line 
anti-tuberculosis medicines well known to be associated with occurrence of joint pain 
(Weyer, 2005). 
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Although the finding of an association between the use of cycloserine-containing anti-
TB regimens and joint pain is an interesting one, it raises even more questions about the 
nature and biological plausibility of this association if one considers the role of 
pyrazinamide and the two fluoroquinolones (ciprofloxacin and levofloxacin).  
 
In a further stratified analysis of the data, the relative risk of pyrazinamide and joint 
pain was 1.02 (p=0.57), and this increased to 1.27 (p=0.75) in a sub-group of patients on 
cycloserine-based anti-TB regimens. The relative risk for the sub-group of patients on 
non-cycloserine-containing regimens could not, however, be determined because one of 
the cross-tabulated cells contained a zero value.  
 
Although the relative risks in both analyses were not statistically significant, the point 
estimate for the sub-group of concurrent pyrazinamide and cycloserine users was 
higher than for that of the pyrazinamide only users. This could be an indication of an 
interaction or effect modification between pyrazinamide and cyloserine and the 
occurrence of joint pain.  
 
Additionally, there could be a pharmacologic interaction between the use of cycloserine 
and efavirenz, which augments the risk of joint pain as has been previously discussed 
under the section on antiretroviral co-medication and the risk of serious adverse events 
during treatment of drug-resistant tuberculosis.  
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But because of the small sample size used in this study, such an association cannot be 
concluded and can only be regarded as a hypothesis generated by the study. Larger 
samples will be required before such sub-analyses can be undertaken. Strom et al. (2005) 
emphasizes that effect modification (or interaction) is useful for generating a new 
hypothesis and that it should always be pursued if it is identified during the analysis of 
data.  
 
Amikacin and ciprofloxacin-based anti-tuberculosis regimens and the risk of 
ototoxicity during DR-TB treatment 
The use of amikacin and ciprofloxacin-based regimens were both independently 
associated with an increased risk of ototoxicity (i.e. hearing loss and tinnitus). This 
finding of ciprofloxacin being a possible risk-factor for ototoxicity should be treated 
with caution, given that 18 (95%) of the 19 patients who were prescribed ciprofloxacin 
were also prescribed amikacin for their individualized anti-TB regimens (p<0.001) 
 
The co-prescription of amikacin and ciprofloxacin could be one of the reasons that 
explain this joint relationship, although both amikacin (an aminoglycoside) and 
ciprofloxacin (a fluoroquinolone) are independent aetiologic agents for ototoxicity 
(Brummett and Fox, 1989; Nadol, 1993; de Jager and van Altena, 2002; Tan, Mulheran, 
Knox and Smyth, 2003; Duggal and Sarkar, 2007; and Selimoglu, 2007).  
 
The role of ciprofloxacin and other fluoroquinolones in causing ototoxicity appears to 
be unclear and doubtful. Evidence in the literature seems to point that topical use of 
ciprofloxacin and fluoroquinolines does not cause damage to the inner ear, although 
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researcher could not find a definitive paper that has evaluated the long-term use or oral 
ciprofloxacin and other fluoroquinolones and ototoxicity (Mudd et al., 2010).   
 
The literature confirms that amikacin and other aminoglycosides are known to cause 
ototoxicity (Arnold, Brouse, Pitcher and Hall II, 2010; Arbex, Varella, de Siqueira and de 
Mello, 2010; Mudd et al., 2010). 
 
Strengths and limitations of the study:  
 
Strengths of the descriptive design 
The data for this study reflects real-life DR-TB treatment practices and patient 
experiences. The cross-sectional descriptive design enabled the researcher to examine 
and describe the prevalence and profile of adverse events in the patient sample. Because 
of this, the researcher was able to generate the tentative hypothesis that some adverse 
events occur more frequently in DR-TB patients who are co-infected with HIV – a fact 
that is clinically important when treating this sub-group of patients.  
 
Limitations of the descriptive design 
By making use of retrospective data, the researcher encountered instances of missing 
patient treatment records and missing data about specific variables. In addition to this, 
it was not possible to perform a qualitative causality assessment of the adverse events 
by using the available data, especially in view of the paucity of the laboratory data.  
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It was also necessary to consider the possibility of the selective or under-reporting of 
adverse events by patients. Some symptoms of the reported adverse events, such as 
nausea, may have overlapped with symptoms of HIV/ AIDS or the adverse effects of 
antiretroviral medicines (Venkatesh, Swaminathan, Andrews and Mayer, 2011).  
The small sample size and the use of data from one facility alone may not allow for 
generalization of findings beyond the studied sample, and this is one notable limitation 
of the study.  
 
Analytic study design: The cross-sectional nature of the study was inherently limited 
in its ability to assess the time-to-adverse event risk profile of the adverse events 
identified in this study. Another major limitation of the study was the inability of the 
cross-sectional design to confirm the temporal sequence of exposure and outcome 
because both exposure and outcome were measured at the same point in time 
(Beaglehole, Bonita and Kjellstrom, 1993).  
 
Sample size and study power: The study made use of a small sample size (n=59), 
and for this reason it was not suitable for the detecting serious adverse effects, most of 
which occur quite rarely. This limitation therefore increased the possibility of Type II 
errors, namely, the failure of the study to detect significant findings in those cases 
where they truly exist. In addition to this, the small size of the sample did not permit a 
detailed sub-group analysis for risk-factor identifications because some of the sub-
groups had either too few or zero numbers. 
 
Measurements: The retrospective nature of data collection may have, to some extent, 
rendered it incapable of accurately and comprehensively measuring the various 
variables of interest in this study. 
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Moreover, the researcher did not conduct causality assessments for individual patient 
medicine and adverse-effect combinations in this study, and also did not assess drug-
drug interactions with ARV medicines. Similarly, since the severity grading was based 
on the MoHSS TB guidelines, it may not have been comparable with the grading 
schemes that were used in other studies.  
 
The pre-defined list of 19 adverse effects (Appendix 6) that are routinely monitored by 
clinicians who are treating patients on MDR-TB treatment may have biased clinicians 
against looking out for any of the other potential adverse effects that were not included 
on this list. In addition to this, this study did not quantify medicine exposure in terms of 
the total dose administered – as calculated from the dose, frequency and duration of 
treatment of each respective medicine.  
 
The specific medicines used in the prior treatment of tuberculosis and the previous 
adverse effects that were experienced by patients whose records were reviewed, were 
not examined. Information about the previous experiences of patients with first-line TB 
medicines and other treatment regimens was missing.  
 
The laboratory monitoring of key organ functions such as those of the liver and kidney, 
appears not to have been carried out in a structured and regular manner. This may have 
reduced the chances of detecting any hepatic and renal damage.  
The symptomatic description of some of the less objective adverse events, such as 
fatigue or dizziness, was not specific enough to describe a particular adverse effect.  
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The time before the onset of adverse effects and their duration, may not have been 
precisely determined in the way that they were documented in the patient treatment 
records. 
 
Generalisability of findings: The findings of this study may not be generalized to the 
whole of Namibia because of the possible non-representativeness of this single-site 
study sample. A study with a more representative sample that includes other drug-
resistant tuberculosis treatment sites is therefore necessary in order to obtain more 
generalisable findings. 
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8. CONCLUSIONS AND RECOMMENDATIONS 
Conclusions 
The prevalence of adverse events in the patients included in this study was 90%. A 
range of adverse events are frequently experienced by patients on second-line anti-
tubercular treatment, especially during the intensive phase of treatment.  
 
In the studied setting, the most frequently observed adverse events during treatment of 
DR-TB were the following: ototoxicity (decreased hearing and tinnitus) (70%); 
gastrointestinal disorders (64%); joint pain (28%); headache (21%); fatigue (19%); 
dizziness (15%) and rash (13%). Some adverse events such as abdominal pains, rash and 
nausea were more frequently observed in HIV-infected DR-TB patients than among 
HIV-uninfected ones.  
 
The observed adverse events were tolerated by 85% of the patients. Most of these 
adverse effects were mild and either resolved by themselves within 3 months of 
treatment and without need for intervention, or required only symptomatic and 
adjuvant treatment. Most of the patients recovered from these adverse effects without 
any known serious medical consequences.  
 
A number of risk factors that are associated with the occurrence of adverse events in 
patients treated for DR-TB were identified. The first two weeks of DR-TB treatment 
were associated with the highest risk of adverse events. Moderate-to-severe adverse 
events were mostly experienced after four weeks of DR-TB treatment. Drug-resistant TB 
patients who were co-infected with HIV were more prone to experiencing three or more 
adverse events. Patients who were co-treated with efavirenz-based HAART were at an 
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increased risk of experiencing moderate-to-severe adverse events, notably joint pains 
(arthralgia). Those treated with zidovudine-based HAART were at an increased risk of 
experiencing nausea. Females were associated with an increased risk of skin rash.  
 
Among patients who were treated for mono-and poly-drug-resistant TB, those with a 
low baseline body weight (≤45 kilograms) were at an increased risk of decreased 
hearing and suffering from adverse gastrointestinal events. The use of cycloserine-
based DR-TB regimens was a risk factor for joint pain, while the use of amikacin-
containing and ciprofloxacin-containing regimens was associated with an increased risk 
of ototoxicity. 
 
An accurate knowledge of the risk factors associated with particular adverse reactions 
by patients to medicines will help doctors and other clinicians to design interventions to 
prevent or minimize the future occurrence of medication-related adverse effects in 
patients (Pirmohamed, Breckenridge, Kitteringham & Park, 1998; Riedl & Casillas, 
2003). This study, therefore, was able to generate the information that was needed about 
the types, frequency, characteristics and risk-factors associated with adverse events of 
drug-resistant anti-TB chemotherapy so that clinicians could make informed choices 
about the attention, resources and efforts that would be needed for the prevention and 
clinical management of the serious adverse reactions that are frequently caused by 
second-line anti-TB medicines, as recommended by Zaleskis (2006). 
 
Most importantly, the findings of the risk factor analysis should be interpreted with 
caution because of the low sample size which severely restricted the scope of this study. 
Nonetheless, the National Tuberculosis Control Program should continue to encourage 
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clinicians who are treating DR-TB patients to closely monitor, document and manage 
adverse events with second-line anti-TB therapy.  
 
Therefore, clinicians should pay particular attention to monitoring, preventing and 
managing adverse events in patients on DR-TB therapy, especially during the intensive 
phase of treatment and in HIV co-infected patients, so as to minimize treatment-related 
intolerance and morbidity; and optimize patients’ adherence to treatment and the 
outcomes of drug-resistant tuberculosis therapy.  
 
Recommendations 
 
 Policy and Practice: Except for serious ototoxicity, most of the medicines used in 
second-line TB treatment regimens are associated with generally tolerable and 
manageable adverse events. The current practice of close and regular monitoring of 
adverse events of TB chemotherapy at the study facility is highly commendable and 
should be encouraged so that the adverse events can be detected and managed 
sufficiently early to prevent any serious injury to patients.  
 
The careful, intensive, aggressive and close follow-up of patients, especially during the 
intensive phase of second-line TB chemotherapy for the early detection and 
management of serious adverse events should be considered by clinicians and the TB 
program managers.  
 
Before discharging patients from the hospital after the completion of the intensive phase 
of treatment, patients should be counseled on the nature of the adverse medication 
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effects that they might expect during their continuation phase of second-line anti-
tuberculosis treatment, and they should be told what to do if they find that they do in 
fact experience such treatment-related adverse effects. 
 
Future research:   
A longitudinal, prospective observational design should be applied to quantify the 
magnitude of risk and determine the time-profile of the risk of the serious adverse 
effects of second-line anti-TB regimens, particularly ototoxicity.  
 
The association of joint pain and use of cycloserine should be verified by subsequent 
studies using designs that are appropriate for proving causation. 
 
The two important research questions arising from this research, which may be pursued 
in follow-up studies, are: 
1. Does the concomitant use of pyrazinamide, cycloserine and efavirenz increase 
the risk of joint pain (arthralgia) during treatment of drug-resistant tuberculosis? 
 
2. Does the concomitant use of a fluoroquinolone antibiotic, an aminoglycoside and 
a nucleoside reverse transcriptase inhibitor (NRTI) increase the risk of ototoxicity 
during treatment of drug-resistant tuberculosis? 
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10. APPENDICES 
Appendix 1: Data collection form and coding scheme 
S.N Variable  Categories and Codes 
1.  Unique Identification No.  [Text string] 
2.  Date of Birth (DoB) DD/MM/YYYY 
3.  Date of registration in TB clinic (DoR) DD/MM/YYYY 
4.  Date of admission in TB ward DD/MM/YYYY 
5.  Age at registration in TB clinic Years = (DoR-DoB) 
6.  Recorded age  
7.  Gender           1. Male           2. Female 
8.  Initial Wt  in kg ###_________ kg 
9.  Initial BMI  
10.  Employment/ profession/ occupation  
11.  Mother tongue (14 Language Options) Oshiwambo, Damara-Nama, 
Herero, Afrikaans, English, 
Thimbukushu, Rukwangali, 
Rumanyo/ Rugciriku, Subiya, Silozi, 
SeTswana, German, Other, Missing 
 
 
 
 
II 
 
12.  Type of TB disease 1. PTB smear + 
2. PTB smear – 
3. EPTB 
4. Other, specify 
13.  TB diagnostic category New patient, never treated for TB 
Previously treated with 1st line meds 
Previously treated with 2nd line 
meds 
14.  Resistance pattern of Mycobacterium at 
diagnosis 
1. Poly resistance 
2. MDR 
3. XDR 
4. Data not available 
15.  Date intensive TB treatment was started 
(DoiStart) 
DD/MM/YYYY 
16.  Date continuation TB treatment was started 
(DocStart) 
DD/MM/YYYY 
17.  Date TB treatment stopped (DotxStop) DD/MM/YYYY 
18.  Duration of intensive phase treatment Days= (DocStart- DoiStart) 
19.  Duration of continuation phase treatment Days= (DotxStop - DocStart) 
20.  Total treatment duration Days= (DotxStop - DoiStart) 
 
 
 
 
III 
 
17.  Treatment regimen 
 
Amikacin, Capreomycin, Cefoxitin, 
Clarithromycin, Cycloserine, 
Ethambutol Ethionamide, 
Kanamycin, Levofloxacin, Para-
aminosalicylic acid, Pyrazinamide, 
Streptomycin, Isoniazid, Rifampicin 
18.  Number of medicines in the intensive phase 
of TB regimen 
 4 
 5 
 6 
 7 
 8 and more 
19.  History of change in TB treatment  regimen  Yes 
 No 
20.  Reason for change in TB treatment regimen   Adverse effects 
 Treatment failure 
 Others, specify 
21.  Concomitant medications ARVs (specify) , Pyridoxine, 
Cotrimoxazole, Contraceptives, 
other (specify) 
22.  HIV status  Positive 
 Negative 
 Unknown 
23.  Other Co-morbidities/ Conditions Diabetes, Hypertension, Asthma, 
Peptic ulcers, Renal disease, Hepatic 
disease, Psychiatric disorder, Drug 
and alcohol abuse, Other (specify)    
 
 
 
 
IV 
 
24.  Occurrence of adverse reaction  Yes 
 No 
25.  Treatment phase when ADR occurred 1. Intensive phase 
2. Continuation phase 
3. Not applicable 
26.  Date of onset of ADR (D_onset) DD/MM/YYYY 
27.  Days to onset of ADR  
28.  Brief description of the adverse reaction/s 
e.g. rash on the skin 
Text 
Consider Coding using the WHO-
ART codes of system organ class/ 
preferred terms 
29.  Relevant Laboratory evidence (values)  
30.  Duration of ADR  
31.  Severity grading of the ADR 1. Mild; requiring no 
intervention 
2. Moderate; requiring 
intervention  
3. Severe; requiring change in 
treatment or hospitalization 
4. Fatal   
32.  Outcome of ADR List of outcomes 
 
Adapted from the MDR-TB Patient Treatment Card. MoHSS, 2006: 184 (Annexure 17) 
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Appendix 3: Study Approval by the Research Committee of the Ministry of 
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Appendix 4: Request for permission to collect data at the study facility  
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Appendix 5: Permission to collect data at the study facility  
 
 
 
 
 
 
IX 
 
Appendix 6: MDR-TB drug side effect monitoring form 
Part A: Intensive phase DR-TB drug adverse effects monitoring form  
Annex 18   No.  9-0/0031A                                                                                                                                                                                             
       
DRUG RESISTANT TUBERCULOSIS SIDE-EFFECT MONITORING FORM 
INTENSIVE PHASE 
Advers
e effect 
(indicat
e 
grading
*) 
Week Manag
ement 
Outco
me 
1 2 3 4 5 6 7 8 9 1
0 
1
1 
1
2 
1
3 
1
4 
1
5 
1
6 
1
7 
1
8 
1
9 
2
0 
2
1 
2
2 
2
3 
24   
Abdomin
al pain 
                          
Constipa
tion 
                          
Decreas
ed 
hearing 
                          
Depressi
on 
                          
Diarrhea                           
Dizzines
s 
                          
Fatigue                           
Fever                           
Headach
e 
                          
Joint 
pain 
                          
Nausea                           
Psychosi
s 
                          
Rash                           
Skin dis-
colouriza
tion 
                          
Tiinitus                           
Tremors                           
Vision 
changes 
                          
Vomiting                           
Other 
(list) 
                          
                           
* Grading: 1 = mild; requiring no intervention             2 = moderate; requiring palliative intervention                 3 = 
severe; requiring change in treatment 
 
 
 
 
X 
 
 
Part B: Continuation phase DR-TB drug adverse effects monitoring form  
 
DRUG RESISTANT TUBERCULOSIS SIDE-EFFECT MONITORING FORM 
Continuation phase 
Adverse effect 
(indicate 
grading*) 
Month ** Management Outcome 
                      
Abdominal pain                       
Constipation                       
Decreased 
hearing 
                      
Depression                       
Diarrhea                       
Dizziness                       
Fatigue                       
Fever                       
Headache                       
Joint pain                       
Nausea                       
Psychosis                       
Rash                       
Skin dis- 
colourization 
                      
Tiinitus                       
Tremors                       
Vision changes                       
Vomiting                       
Other (list)                       
                       
                       
                       
* Grading: 1 = mild; requiring no intervention             2 = moderate; requiring palliative intervention                 3 = 
severe; requiring change in treatment 
** Indicate in the first column the month of treatment that continuation phase started 
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Appendix 7: Abstract presented at the ICIUM conference, 2011 
Abstract number 486 
Prevalence and Risk Factors of Adverse Effects of Second-Line Anti-Tuberculous Medicines 
in a Treatment Facility in Namibia: 2009–10 
Problem statement: Namibia reported 372 cases of DR-TB in 2009. Second-line TB medicines 
have more frequent and serious adverse effects (AEs). The high TB/HIV co-infection (58%) is a 
further complicating factor. With little documented information on the profile and risk factors 
of these AEs, managers of tuberculosis control programs, clinicians, and patients face challenges 
in optimizing treatment outcomes. 
Objectives: To determine the types and frequency of AEs of second-line anti-TB medicines in a 
selected DR-TB treatment facility; to identify the AE risk factors 
Design: Cross-sectional. Data were collected from patients’ treatment records using a 
structured form. Descriptive statistics were applied to profile AEs. Logistic regression was used 
to calculate odds ratios [OR; 95% confidence interval (CI), p< 0.05] in risk factor analysis. 
Setting: A district TB treatment facility 
Study population: All patients treated for DR-TB at the study facility from January 2008 to 
February 2010 
Outcome measure(s): Occurrence and characterization of AEs 
Results: Demographics: Male (M) 64%; age (mean years ± SD), 36.9 ± 8.4 (M), 31 ± 10.2 (F); initial 
weight (mean kg ± SD), 53.6 ± 7.8 (M) and 49.8 ± 16.4 (F) 
In total, 141 AEs were experienced in 90% (53/59) patients. Gastrointestinal tract (GIT) events 
were 64%, tinnitus 45%, joint pain 28%, and decreased hearing 25%. In 53% of patients, AEs 
resolved within 3 months. AEs were severe, requiring discontinuation of suspected medicine in 
15% of patients, 9% recovering with sequelae. 
 
 
 
 
XII 
 
Risk-factor analysis: Moderate-severe AEs were associated with HIV co-infection (OR 3.12; 95% 
CI 1.04–9.33, p= 0.04). AEs lasting >3 months were associated with ARV co-medication (OR 7.88; 
95% CI 1.11–56.12, p=0.04). GIT effects were mostly experienced in the first month of DR-TB 
treatment (OR 4.29; 95% CI 1.25–14.73, p=0.02). Nausea was associated with AZT-based HAART 
(OR 7.50; 95% CI 1.09–51.51, p=0.04) and joint pain with the use of cycloserine-containing 
regimens (OR 6.35; 1.56–25.84, p=0.01). Risk of rash in females was OR 15.86; 95% CI 1.75–143.74, 
p=0.01. In 18 patients with mono/poly-resistant TB, low baseline body weight (≤45 kg) increased 
risk of GIT events (OR 16.50; 95% CI 1.10–250.2, p=0.04) and decreased hearing (OR 36.00; 95% 
CI 1.71–756, p=0.02). Risk of ototoxicity was highest in patients using amikacin (OR 12.00; 95% 
CI 1.29–111.32, p=0.03) and ciprofloxacin (OR 27; 95% CI 1.98–368.28, p=0.01). Among 37 MDR-
TB patients, HIV co-infection increased risk of experiencing ≥3 AEs (OR 8.00; 95% CI 1.28–50.04, 
p=0.03), mostly moderate-severe AEs (OR 10.42; 95% CI 1.62–66.90, p=0.02). Joint pain occurred 
mostly in patients using cycloserine-based regimens (15.67; 95% CI 1.70–144.35, p= 0.02) and 
efavirenz-based HAART (OR 13.46; 95% CI 1.02–178.30, p=0.05). 
Conclusions: Although AEs were highly prevalent in DR-TB chemotherapy, 85% of patients 
tolerated them. GIT effects and hearing loss were most common. Findings of risk-factor analysis 
are statistically imprecise, inconclusive, and require further study. 
 
 
 
 
 
 
